Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology by Hoang-Xuan, K et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Diagnosis and treatment of primary CNS lymphoma in immunocompetent
patients: guidelines from the European Association for Neuro-Oncology
Hoang-Xuan, K; Bessell, E; Bromberg, J; Hottinger, A F; Preusser, M; Rudà, R; Schlegel, U; Siegal, T;
Soussain, C; Abacioglu, U; Cassoux, N; Deckert, M; Dirven, C M; Ferreri, A J; Graus, F; Henriksson,
R; Herrlinger, U; Taphoorn, M; Soffietti, R; Weller, M
Abstract: The management of primary CNS lymphoma is one of the most controversial topics in neuro-
oncology because of the complexity of the disease and the very few controlled studies available. In
2013, the European Association of Neuro-Oncology created a multidisciplinary task force to establish
evidence-based guidelines for immunocompetent adults with primary CNS lymphoma. In this Review,
we present these guidelines, which provide consensus considerations and recommendations for diagnosis,
assessment, staging, and treatment of primary CNS lymphoma. Specifically, we address aspects of care
related to surgery, systemic and intrathecal chemotherapy, intensive chemotherapy with autologous stem-
cell transplantation, radiotherapy, intraocular manifestations, and management of elderly patients. The
guidelines should aid clinicians in their daily practice and decision making, and serve as a basis for future
investigations in neuro-oncology.
DOI: 10.1016/S1470-2045(15)00076-5
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-114449
Accepted Version
 
 
Originally published at:
Hoang-Xuan, K; Bessell, E; Bromberg, J; Hottinger, A F; Preusser, M; Rudà, R; Schlegel, U; Siegal, T;
Soussain, C; Abacioglu, U; Cassoux, N; Deckert, M; Dirven, C M; Ferreri, A J; Graus, F; Henriksson,
R; Herrlinger, U; Taphoorn, M; Soffietti, R; Weller, M (2015). Diagnosis and treatment of primary CNS
lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.
Lancet Oncology, 16(7):e322-332. DOI: 10.1016/S1470-2045(15)00076-5
                             Elsevier Editorial System(tm) for The Lancet Oncology 
                                  Manuscript Draft 
 
 
Manuscript Number: THELANCETONCOLOGY-D-14-01617R2 
 
Title: EANO Guideline for the diagnosis and treatment of primary CNS lymphoma in immunocompetent 
patients  
 
Article Type: Review (Post author-enquiry) 
 
Keywords: primary CNS lymphoma,  
intraocular lymphoma,  
chemotherapy,  
radiotherapy,  
intrathecal,  
rituximab,   
corticosteroids,  
autologous stem cell, 
intravitreal chemotherapy,  
elderly,  
CSF,  
neurotoxicity 
prognostic factors,  
 
 
Corresponding Author: Prof. Khe HOANG-XUAN, MD PhD 
 
Corresponding Author's Institution: Hôpital de la Pitié Salpêtrière, Division Mazarin 
 
First Author: Khe HOANG-XUAN, MD PhD 
 
Order of Authors: Khe HOANG-XUAN, MD PhD; Eric Bessell, MD; Jacoline Bromberg, MD; Andreas 
Hottinger, MD; Matthias Preusser, MD; Roberta Ruda, MD; Uwe  Schlegel, MD; Tali Siegal, MD; Carole 
Soussain, MD; Ufuk Abacioglu, MD; Nathalie Cassoux, MD; Martina Deckert, MD; Clemens Dirven, MD; 
Andrés Ferreri, MD; Francesc Graus, MD; Roger Henriksson, MD; Ulrich Herrlinger, MD; Martin 
Taphoorn, MD; Riccardo Soffietti, MD; Michael Weller, MD 
 
Manuscript Region of Origin: FRANCE 
 
Abstract: The management of primary central nervous system (PCNSL) is one of the most controversial 
topics in neuro-oncology because of the complexity of the disease and the very limited number of 
controlled studies available. In 2013, the European Association of Neuro-Oncology (EANO) created a 
multidisciplinary task force to establish evidence-based guidelines for immunocompetent adult 
patients with PCNSL. The guideline provides consensus considerations and recommendations for 
diagnosis, staging and treatment of PCNSL, including surgery, systemic and intrathecal chemotherapy, 
intensive chemotherapy with autologous stem cell transplantation, radiotherapy, intraocular 
manifestations, and specific management of elderly patients. The guideline should aid the clinicians in 
everyday practice and decision making and serve as a basis for future research in the field. 
 
 
 
 Dear Editor, 
 
Thank you for your suggestions to improve further our paper. Please, find in attached file our revised 
manuscript which have take into account all your editorial recommendations. You will find below our 
point by point replies to your editorial comments. We hope that you will find now the manuscript 
suitable for publication in Lancet Oncology. 
 
Kind regards 
 
Khe Hoang-Xuan, MD,PhD 
 
Responses to the Editor comments 
1) In response to Reviewer 1, comment 2, please revert and move the intraocular lymphoma section back to 
the appendix as in the original version. 
RESPONSE:  The intraocular lymphoma section is now back to the appendix with the corresponding references 
 
2) In response to your reply to Reviewer 2, comment 1, please leave the tables as they are. 
RESPONSE: OK 
 
3) In response to your reply to comment 3 from Reviewer 3 (regarding guidelines for treatment of patients for 
which there are no evidence based recommendations), please summarize your reply and add it to the text to 
clarify that it is not possible to provide evidence-based recommendations for patients with tumours that 
cannot be or are too risky to biopsy. 
RESPONSE: Two sentences have been added in the general recommendation section (p.4) 
“Our guideline covers treatment of histologically or cytologically proven PCNSL. We have not covered 
specifically the treatment of patients with deep seated tumours not  readily amenable to biopsy for which there 
are no evidence-based recommendations. We believe that biopsies are almost always possible in specialized 
centers and that chemotherapy and/or  radiotherapy interventions without histological confirmation of PCNSL 
should be discouraged.” 
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Abstract 
 
The management of primary central nervous system (PCNSL) is one of the most controversial topics 
in neuro-oncology because of the complexity of the disease and the very limited number of controlled 
studies available. In 2013, the European Association of Neuro-Oncology (EANO) created a 
multidisciplinary task force to establish evidence-based guidelines for immunocompetent adult 
patients with PCNSL. The guideline provides consensus considerations and recommendations for 
diagnosis, staging and treatment of PCNSL, including surgery, systemic and intrathecal chemotherapy, 
intensive chemotherapy with autologous stem cell transplantation, radiotherapy, intraocular 
manifestations, and specific management of elderly patients. The guideline should aid the clinicians in 
everyday practice and decision making and serve as a basis for future research in the field. 
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Introduction 
 
Primary central nervous system lymphomas (PCNSL) are extranodal malignant non-Hodgkin 
lymphomas (NHL) of the diffuse large B cell (DLBCL) type confined to the brain, eyes, 
leptomeninges, or spinal cord in the absence of systemic lymphoma. Currently PCNSL are estimated 
to account for up to 1% of lymphomas, 4-6% of all extranodal lymphomas, and about 3% of all CNS 
tumors.1 After a continuous increase in the 1980’s and 1990’s, epidemiologic data in Western 
countries show a decrease in the incidence of PCNSL, particularly among young patients suffering 
from AIDS.2 In contrast, the incidence continues intriguingly to rise in the elderly who represent 
consequently the large majority of patients in the immunocompetent population in some recent 
studies.3-5 Although the prognosis of PCNSL remains poor, it has significantly improved over the past 
two decades as a result of better treatment strategies with a curative aim. Treatment of PCNSL is 
challenging. Despite a high chemosensitivity and radiosensitivity, remissions are frequently short-
lasting; the blood brain-barrier (BBB) limits the access of many drugs to the CNS; and patients, 
especially the elderly, are at high risk of developing severe treatment related-neurotoxicity. To date, 
therapeutic knowledge to define the optimal treatment mainly results from retrospective series or 
single arm phase II studies, with only three completed randomized trials available: one phase III and 
two phase II. The objective of this guideline is to provide clinicians with evidence-based 
recommendations and consensus expert opinions on the management of patients with PCNSL. The 
present guideline focuses on the immunocompetent population which represents the vast majority of 
the patients today. PCNSL of immunodeficient patients and the rare indolent low grade lymphomas 
occurring primarily in the CNS, which have a distinct pathogenesis with separate diagnostic and 
therapeutic implications, will be subject to specific guidelines.  
 
Search strategy and selection criteria  
 
The guideline task force was set up in 2013 under the auspices of the EANO (European Assocation for 
Neuro-Oncology) and selected to be representative of European-based medical experts (10 countries). 
The panel covered all fields of expertise in the management of PCNSL, i.e. neurologists, 
haematologists, medical oncologists, neurosurgeons, pathologists, ophthalmologists and radiation 
oncologists. Based on best available evidence from literature review, the writing group (EB, JB, AH, 
KHX, MP, RR, US, TS, CS) produced the draft guideline, which was subsequently submitted to the 
review committee (UA, NC, MD, CD, AF, FG, RH, UH, RS, MT, MW). The revised guideline, taking 
into account the comments of the reviewers, was resubmitted by the chairman to the whole task force 
for review and amendments twice. Therafter, final agreement was obtained in September 2014. When 
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analyzing results and drawing recommendations, at any stage, differences were resolved by 
discussiondiscussion and, if persisting, were reported in the text. References for this review were 
identified through searches of PubMed with the search terms ”primary CNS lymphoma”,”primary 
central nervous system lymphoma”, “primary intraocular lymphoma”, “elderly”, “radiotherapy”, 
“chemotherapy” and “rituximab” from January 1980 to September 2014. Articles were also identified 
through searches of the authors` own files. The final reference list was generated on the basis of 
originality and relevance to the broad scope of this review. Abstracts presented at the annual ASCO 
meeting in 2013 and 2014 relevant to the topic were included by task force members during 
manuscript preparation. The scientific evidence of papers collected from the literature was evaluated 
and graded as follows and recommendations were given accordingly. Class I evidence was derived 
from prospective, randomized, phase III clinical trials; class IIa evidence was derived from prospective 
randomized phase II trials, class IIb evidence was derived from phase II trials; class IIIa was derived 
from prospective studies, including observational studies, cohort studies and case–control studies; 
class IIIb evidence was derived from retrospective studies; class IV evidence was derived from 
uncontrolled case series, case reports and expert opinion. As for recommendations, level A required at 
least one class I study or two consistent class IIa studies, level B at least one class IIa study or 
overwhelming class IIb and III evidence and level C at least two consistent class III studies. 
Pathology, genetics, clinical features and neuroimaging were simply reviewed but not graded. When 
suﬃcient evidence for recommendations A–C was not available, we gave a recommendation as a 
“Good Practice Point”, if agreed by all members of the Task Force.  
 
General recommendations 
 
Consensus statements and recommendations for the general approach to patients with PCNSL, 
including: 1/ pathology and genetics, 2/ clinical presentation, 3/ diagnostic confirmation, 4/ 
neuropathology of corticosteroid-treated PCNSL, 5/ neuroimaging, 6/ cerebrospinal fluid (CSF) 
analyses,  7/ vitreous analyses, 8/ staging, 9/ prognostic factors, 10/ response criteria to treatment, and 
11/ treatment-related neurotoxicity are presented in table 1. The evidences used to establish these 
recommendations are detailed in the supplementary webappendix. Key recommendations for treatment 
are summarized in table 2. The evidences concerning intraocular lymphoma are presented in the 
webappendix.  Our guideline covers treatment of histologically or cytologically proven PCNSL. We 
have not covered specifically the treatment of patients with deep seated tumours not  readily amenable 
to biopsy for which there are no evidence-based recommendations. We believe that biopsies are almost 
always possible in specialized centers and that chemotherapy and/or  radiotherapy interventions 
without histological confirmation of PCNSL should be discouraged.  
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 Surgery 
 
Although very few data are available in the literature, surgery has traditionally been considered to 
have no role in the treatment of PCNSL. This widely adopted opinion is based on small retrospective 
series suggesting no clear benefit in outcome of surgical resection used as sole treatment compared 
with supportive care (Class IIIb),6 and compared with biopsy in patients having received post-
operative chemotherapy and/or radiotherapy (Class IIIb).7,8 This may be explained by the 
microscopically multifocal and infiltrative nature of PCNSL that may extend beyond the visible border 
of the lesion.9 The relative radiosensitivity and high chemosensitivity of PCNSL, and the increased 
risks of postoperative morbidity of this patient population have also contributed to discourage surgery. 
However, the recommendation to restrict surgical interventions to biopsies is not based on randomized 
data and, more importantly, not on contemporary data reflecting modern neurosurgery. The German 
PCNSL Study Group–1 phase III trial included an unusually high rate of operated patients, which 
allowed the largest and most recent retrospective analysis of an association of surgery and outcome. A 
significantly longer progression free survival (PFS) and overall survival (OS) in patients with subtotal 
or gross total resections compared with biopsied patients was reported. This difference in outcome was 
independent of post-operative Karnofsky performance status (KPS) and age. Since biopsied patients 
more often had multiple and/or deeply seated CNS lesions than resected patients, these features may 
have contributed to the unfavourable outcome. When adjusted for the number of lesions (site of the 
lesions was not analyzed in the study), the difference in outcome remained significant in term of PFS 
but did not reach the significance threshold for OS (Class IIIa).10  
 
Systemic chemotherapy 
The CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) regimen commonly used for 
systemic NHL induces short-lasting responses in PCNSL and its addition to radiotherapy has not 
shown a survival benefit in prospective trials (Class IIb).11-13 This inefficacy is probably due to the fact 
that phosphoramide mustard and doxorubicin are not able to cross the blood-brain barrier (BBB) to 
eradicate microscopic disease. Based on convergent results from numerous prospective and 
retrospective studies, high-dose (HD) intravenous (iv) methotrexate (MTX), an antifolate and 
antimetabolite, is now considered the most important and beneficial single agent. Penetration of MTX 
into the CNS depends both on the total dose and rate of infusion. The optimal dose of MTX has not 
been determined. It has been estimated that the iv MTX should range between 1 g/m2 and 8 g/m2 to 
cross the BBB. In the absence of clear evidence for dose-response relationship, and since rapid 
infusion of MTX ≥ 3g/m2 over 3 hours achieves cytotoxic levels in the CSF, there is a growing 
consensus to deliver MTX according to this protocol (Class IV).14 Since efficacy of MTX may also 
depend on duration of exposure, MTX administration interval should range between 10 days and 3 
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weeks (Class IV).15 The optimal number of MTX injections to deliver is unknown. A minimum of 4-6 
injections is delivered in most chemotherapy regimens, especially if no consolidation treatment 
(radiotherapy and/or intensive chemotherapy) is scheduled in the protocol. For patients who achieved 
only partial response (PR) after 4-5 courses of HD MTX, additional courses may improve the 
complete remission rate (Class IIIa).16 Infusions of HD MTX require pre- and post-hyperhydration, 
urine alkalinization, leucovorin rescue and MTX concentration monitoring. Currently most treatment 
protocols combine HD MTX with a variety of other chemotherapeutic agents to improve response rate 
and outcome. The best evidence to support this approach comes from an IELSG randomized phase II 
study comparing HD MTX alone, administered at 3 g/m2/d every 21 days, to HD MTX with 
cytarabine (2 g/m2 twice per day on days 2–3)(Class IIa).17 Both chemotherapy arms were followed by 
WBRT. This study showed a significantly higher complete response (CR) rate in the HD MTX-
cytarabine arm. Regarding secondary endpoints, a significantly improved overall response rate (ORR), 
PFS and a trend towards better OS in the HD MTX-cytarabine arm were noticed. Two previous 
prospective trials evaluating HD MTX at a dose of 8g/m2 as single agent and without immediate 
consolidation WBRT resulted in a shorter PFS when compared to polychemotherapy regimens (Class 
IIb).18,19 Similarly, the addition of ifosfamide to HD-MTX improved response rate, but not survival, in 
the G-PCNSL-SG-1 trial.20 Altogether, these data resulted in the recognition that only HD MTX can be 
defined as a chemotherapy standard of care.21 Chemotherapeutic agents to be combined with HD MTX 
should be selected among active drugs known to cross the BBB, such as HD cytarabine. Recently, the 
CALGB50202 multicenter phase II trial reported promising results using HD cytarabine combined 
with etoposide as consolidation without WBRT following a HD MTX-based polychemotherapy as 
induction regimen (Class IIb).22 In contrast, very disappointing results have been reported in a pilot 
study combining HD MTX (3.5g/m2), thiotepa and cytarabine at a reduced dose of 1g/m2 suggesting 
that the cytarabine dose probably was suboptimal to reach cytototoxic levels in the CNS (Class IIIa),23 
as supported by pharmacokinetic studies.24 Another approach is BBB disruption (BBBD) by intra-
arterial (IA) infusion of hypertonic mannitol followed by intra-arterial (IA) chemotherapy to increase 
the drug concentration in the CNS. BBBD with IA MTX administrated in newly diagnosed PCNSL 
demonstrated a good safety profile and neurocognitive tolerance and achieved comparable outcomes 
to those observed with HD-intravenous MTX based chemotherapy regimens (Class IIIb).25-27 
However, conversely to those reported in prospective studies on chemoradiotherapy, even after a 
follow-up longer than 10 years (Class IIb),28 BBBD is not associated with a plateau in survival curves, 
suggesting a continuum of relapses and deaths. This procedure requires patient selection as safety 
depends on the extent of intracranial mass effect and the procedure is limited to patients with no 
contraindications for general anesthesia. It should be managed by teams trained in BBBD as it is 
complex, requiring cannulation of the intracranial vessels. In summary, HD MTX is the drug of choice 
for PCNSL. In patients who are not eligible for HD MTX, treatment should be chosen from treatments 
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active as salvage in refractory or recurrent PCNSL after initial HD MTX based chemotherapy (see 
salvage treatment section).   
 
Intrathecal chemotherapy 
 
Intrathecal (IT) chemotherapy administration has not been prospectively studied and its efficacy in 
PCNSL remains debated. Three retrospective studies did not demonstrate benefit from the addition of 
intrathecal drugs (MTX, cytarabine) in patients treated with HD MTX dosed at 3g/m2 (Class IIIb).29-31 
In contrast, two consecutive single arm trials using the same systemic polychemotherapy regimen 
suggested additional benefit when intraventricular chemotherapy was added (Class IIIa).32,33 However, 
given the low level of evidence, we currently do not advocate IT chemotherapy as prophylaxis.  
 
Rituximab 
 
Based on its poor penetration into the CNS related to its large size, the maximal concentration and 
efficacy of the anti-CD20 antibody rituximab in the CNS might be assumed to occur in the early 
treatment phase, during BBB breakdown within the tumors. The effect of rituximab when used as 
monotherapy in PCNSL was evaluated in a single study in which 12 patients with refractory or 
relapsed PCNSL were treated with a weekly iv dose of 375 mg/m2 rituximab infusion for up to eight 
doses (Class IV).34 MRI responses were observed in 36% of patients. Other studies used iv rituximab 
in combination with a HD MTX-based chemotherapy regimen as initial treatment for newly-diagnosed 
PCNSL or as salvage treatment for recurrent PCNSL (Class IIIa, Class IIIb and IV).16,22,35-41 Three 
studies suggested that the addition of rituximab to HD MTX-based chemotherapy improves the CR 
and OS ratein patients with newly-diagnosed PCNSL based on retrospective comparison with 
historical controls (Class IIIb).39-41 Overall, the addition of rituximab to systemic polychemotherapy is 
well tolerated. Injection of rituximab into the CSF via either lumbar puncture or by intraventricular 
administration was evaluated in phase I for refractory or recurrent CNS lymphoma patients (Class 
IIIa).42 In these studies objective responses and good tolerability were documented confirming small 
case series. In conclusion, the existing level of evidence supporting either systemic or local use of 
rituximab as part of treatment protocol for PCNSL remains low. Yet, the preliminarily available 
information suggests that it may add some benefit. Two ongoing randomized trials (NCT01011920; 
NTR2427) should clarify the role of systemic rituximab in PCNSL.  
 
Radiotherapy 
 
 8
Because of the microscopically diffuse and multifocal nature of PCNSL, radiotherapy (RT) has so far 
involved the whole brain, including the eyes.  Despite a high response rate in the range of 50%, RT 
used as sole treatment modality, provides limited survival benefit in PCNSL patients, with a median 
OS duration of 10–18 months and a 5-year survival rate of 5%. The only phase II trial, conducted by 
the RTOG, which delivered a total dose of 40 Gy with an additional 20-Gy boost to contrast-
enhancing lesions, reported a disappointing 11.6 month OS (Class IIb).43 In addition, the majority of 
relapses occurred in fields that had received the highest RT dose. Although not formally compared in a 
randomized trial, a wide consensus is shared which considers that HD MTX-chemoradiation is 
superior to RT-alone, allowing for a 2 to 4-fold increase in OS (median: 30-72 months) and long-term 
survivors (5-year survival of 20-50%) for many protocols (Class IIb, IIIa IIIb).15,44-52 In contrast to 
extracerebral NHL, the optimal dose of post-chemotherapy irradiation has never been prospectively 
investigated in PCNSL.53 Doses of 23–50 Gy to the whole brain, with or without a tumor bed boost, 
are currently used, with most of the protocols delivering a total dose of 40–45 Gy without boost, and 
standard fractionation (1.8-2Gy/fraction). The RTOG-9310 trial did not show a clear benefit with 
hyperfractionated WBRT (Class IIb).54 For patients who achieve a CR after HD MTX-based 
chemotherapy, it remains unclear whether consolidation with WBRT provides better disease control or 
survival. There has only been one randomized trial of radiotherapy versus watch-and-wait after 
chemotherapy for PCNSL. This study (G-PCNSL-SG 1) conducted in Germany was a non-inferiority 
phase III trial, in which patients received HD MTX 4g/m2 iv every 14 days for 6 cycles with or 
without ifosfamide. Those patients who achieved a CR had been randomized initially between 
consolidating WBRT, 45 Gy in 30 fractions over 6 weeks or no further immediate treatment. Patients 
without a CR received HD cytarabine or WBRT. A total of 551 patients entered the study, but 318 
patients were treated per-protocol. OS was similar in both arms. In the whole per-protocol population, 
the WBRT arm was associated with a trend (not significant) for better PFS, as compared with the no 
WBRT arm but with no significant difference in OS.20 This trial (Class I), which is, to date, the largest 
one and only phase III trial in PCNSL has raised vigourous debate within the community.55-58 Several 
experts consider that the unmet primary endpoint for non-inferiority and the high rate of protocol 
violations prevent any conclusions being drawn from the trial and advocate keeping consolidation 
WBRT after HD MTX-based chemotherapy as the standard of care, whilst awaiting results from 
further, ongoing randomized trials; while others, acknowledging the methodological limitations of the 
study, consider nevertheless that the results contribute strongly to the accumulating retrospective 
literature suggesting that omission of WBRT from first-line treatment results in shorter PFS but does 
not compromise OS (Class IIIb).29,59,60 In addition, several single arm trials have suggested that 
chemotherapy alone, plus a deferred RT strategy may result in comparable OS with those reported for 
combined chemo-RT but with better neurocognitive preservation (Class IIb, IIIa, IIIb).19,25,26,32,61-63 
Since withdrawing consolidation WBRT for patients with CR to chemotherapy remains controversial, 
especially in patients less than 60 years old who are at lower risk of developing neurotoxicity, reduced 
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dose WBRT is another alternative approach. Conflicting results have been reported. A subset analysis 
from a phase II trial that included 25 patients aged <60 years who achieved a CR after initial 
chemotherapy and received either 45 Gy or 30.6 Gy as consolidation treatment showed a significantly 
higher recurrence rate and lower OS rate in the reduced-dose RT group (Class IIIb).64 On the other 
hand, in a restrospective study of 33 patients with PCNSL who achieved CR after MTX-containing 
chemotherapy and were referred to consolidation WBRT, total doses ≥ 40 Gy were not associated with 
improved disease control in comparison with a WBRT dose of 30-36 Gy (Class IIIb).65 More recently, 
a phase II trial evaluating an immunochemoradiation regimen (R-MPVA) including rituximab and HD 
MTX-based polychemotherapy, the 31 CR patients were offered reduced dose WBRT (23 Gy in 
complete responders) with encouraging results both in term of survival and neurotoxicity (Class IIb).16 
Based on these results, a randomized phase II study (RTOG-1114) comparing the R-MPV regimen 
with or without reduced-dose WBRT is currently ongoing (NCT01399372). In summary, the role of 
consolidation WBRT following HD-MTX based chemotherapy remains debated especially in patients 
in CR. In addition, the optimal dose has not been defined yet. 
 
High-dose chemotherapy, myeloablative conditioning and autologous stem cell transplantation (HDC 
/ASCT) 
 
HDC/ASCT is the standard treatment for chemosensitive relapsing systemic DLBCL. For patients 
with relapsed or refractory PCNSL, there is only one multicenter phase II trial evaluating HDC/ASCT, 
with TBC conditioning regimen (thiotepa, busulfan, cyclophosphamide). The CR rate was 60%, 
median PFS and OS were 41 and 58 months respectively for the 27 patients out of 43 who completed 
the full HDC/ASCT procedure. For the whole population of this trial, the intent-to-treat median PFS 
and OS times were 11 and 18 months respectively. The toxicity-related mortality was 7% (Class IIb).66 
An update of this study to which additional cases have been included, and an independent 
retrospective single center series confirmed the benefit of the TBC regimen followed by ASCT (Class 
IIIb).67,68 Experiences with other HDC regimens in this setting of patients are limited to a few cases, 
which prevent any conclusions being drawn. Because of its toxicity risks, the HDC/ASCT is likely to 
be proposed for younger patients (<60-65 years) with a good performance status, which makes it 
difficult to compare with other salvage treatments, including second-line conventional chemotherapy 
regimens and WBRT. The specific role of HDC/ASCT as consolidation in first-line treatment is 
difficult to evaluate since WBRT was administered after HDC/ASCT in early studies (Class IIb).69,70 
The first study with HDC/ASCT without WBRT used the BEAM regimen (BCNU, etoposide, 
cytarabine, and melphalan) as conditioning and reported a disappointing median event-free survival of 
9.3 months (Class IIIa).71 Subsequently, encouraging studies for which WBRT had been omitted at 
least in patients in CR after HDC/ASCT using HD thiotepa-based conditioning regimens have been 
reported (Class IIIb and IV).72-75 Taken together, although direct comparison between conditioning 
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regimens applied is difficult, HD thiotepa-based conditioning regimens seem more efficient than 
BEAM-based regimens. In summary, HDC/ASCT represents an effective treatment option for selected 
refractory and relapsed PCNSL patients, but should be reserved to experienced centers. Superiority of 
the HDC/ASCT approach compared to standard combined chemo-radiotherapy as first line treatment 
has not been proven and is currently under investigation in two ongoing trials (NCT00863460, 
NCT01011920). 
 
Elderly patients 
 
Definition of ‘elderly’ is not uniform. However, in the studies available which have evaluated 
prognostic factors, older ages (over 50 and over 60) were consistently correlated with worse outcome 
(see the section on prognostic factors in appendix). Furthermore, for chemoradiation-induced 
neurotoxicity age>60 was found to be highly prognostic (see the section on neurotoxicity in appendix). 
Therefore, age of 60 has been used as cut-off to define the elderly population in most of the studies. 
Four prospective studies have been published on treatment of elderly patients with PCNSL (Class 
IIb),36,63,76,77 seven prospective studies on patients of all ages but reporting specifically on older 
patients (Class IIIa),11,12,32,43,52,54,78 and seven retrospective studies reporting on ≥ 15 patients (Class 
IIIb).79-85 As in younger patients, results in patients treated with steroids or CHOP/CHOD in addition 
to radiotherapy do not differ from results after radiotherapy only (Class IIb).11,12,43,77 In the RTOG 
phase II trial, the median survival was only 7.8 months.43 After HD-MTX-based therapy, defined as 
dose of MTX ≥ 1 g/m2 PFS in patients aged 60 or 65 and older is reported between 6 and 16 months 
and OS between 14 and 37 months (Class IIb and Clas III) with OS in the majority of prospective 
studies under 2 years.32,36,52,54,63,73,78-85 Other than within retrospective studies no direct comparisons 
have been made between treatment with HD-MTX-based chemotherapy and radiotherapy in this age 
group.81 However, the impression from the single arm studies is that survival after chemotherapy is at 
least as good and probably better after HD MTX-based chemotherapy than after radiotherapy (Class 
IV). Formal comparisons of different HD MTX-based regimens have not been published but in a 
recently completed randomized phase II study, toxicity was identical, CR rate, median PFS and  
survival appeared better after MPV-A (MTX, procarbazine, vincristine, cytarabine) than after MTX 
and temozolomide though the difference was not significant (Class IIa).86 Five prospective studies 
report on chemotherapy toxicity in patients aged over 60. With the exception of one study, in which an 
intensive multi-drug regimen was used and toxicity was exceedingly high in older patients,52 HD 
MTX-based chemotherapy up to 3.5 g/m2 was well tolerated with 2-7% treatment-related mortality, 
less than 10%  grade 3-4 nephrotoxicity and 7-10% of patients discontinuing treatment due to 
chemotherapy-associated toxicity, though MTX dose was reduced because of decreased renal function 
in 26-44% of patients.36,63,76,87 Retrospective studies substantiate this view. Thus, in general, older 
patients tolerate treatment with HD-MTX well when adequate supportive measures are used and renal 
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function is accurately monitored.3 As discussed in the neurotoxicity section (appendix), risk of delayed 
leukoencephalopathy is particularly high in patients older than 60 years managed with 
chemoradiotherapy. For patients treated with HD-MTX-based chemotherapy without radiotherapy no 
studies reporting specifically on older patients are available, but reports including neuropsychological 
assessment of patients of all ages show little or no cognitive decline compared with post-treatment 
evaluations (Class IIIb).61,88 Given the available data on acute and long-term toxicity of radiotherapy 
and chemotherapy in older patients with performance status KPS ≥ 70, treatment with HD MTX-based 
chemotherapy with deferral or elimination of WBRT is the treatment of choice. In older patients in 
poor condition and in the very old (over 80) who both have a worse prognosis,85 the acute morbidities 
and frequent admissions to hospital associated with HD-MTX chemotherapy need to be individually 
weighed against the more limited survival benefits in this population.  
 
 Salvage treatment 
About one third of patients with PCNSL will present with disease that is refractory to first-line 
treatment and half of responders will relapse despite high response rates seen with initial treatment. 
The prognosis of progressive or relapsed PCNSL remains poor with limited treatment options. Salvage 
treatments for relapsed or refractory PCNSL patients depend on age, performance status, site of 
relapse within the CNS, prior treatments and time duration from last response. If the patient did not 
receive any consolidating treatment after the HD MTX-based induction chemotherapy, WBRT or 
HDC/ASCT should be considered. Two retrospective studies have evaluated WBRT delivered in 
relapsed PCNSL and reported a high rate of objective reponses and a short median survival of 11-16 
months - quite similar to what is expected with WBRT alone as initial treatment (Class IIIb).89,90 
Delayed neurotoxicity occurred in 15%–22% of patients. However, in the setting of recurrence, 
WBRT did not prolong survival compared with non-WBRT-based therapies in the G-PCNSL-SG-1 
trial (Class IIIa).20 HDC/ASCT is an efficient alternative option, as has been previously discussed, and 
which should be preferentially proposed for patients aged < 60-65 years and with a tumour sensitive to 
second-line chemotherapy (Class llb) (see section above).66-68 Otherwise, if the patient is not suitable 
for WBRT or HDC/ASCT , conventional chemotherapy can be proposed as second-line treatment. 
There is however, only a limited number of prospective studies available for guidance and these have 
been single-arm phase ll trials complicating any comparison across trials ( Class llb, lll and lV  for all 
studies in this section ). Several drugs used as single agent or in combination, with or without 
rituximab, have been evaluated and demonstrated modest activity such as temozolomide,38,91 
topotecan,92 pemetrexed,93 bendamustine,94 PCV regimen,95 ifosfamide-etoposide based regimen,37,96, 
or cisplatin-cytarabine based regimen.97 MTX rechallenge given as single agent or in combination may 
also yield a high rate of new objective response and durable remission in patients who previously 
achieved prolonged response with HD MTX-based chemotherapy, suggesting retained 
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chemosensitivity to MTX (Class III).98,99 Extra-CNS relapses account for 7% of failures, and some 
studies suggest that extra-CNS relapses are associated with a better prognosis than CNS-involving 
relapses;100 the best salvage treatment for this condition remains to be defined, but excellent results 
have been reported with anthracycline-based chemotherapy consolidated or not with HDC/ASCT.28  
 
Conclusions 
Guidelines reflect the state of knowledge at a given timepoint. The EANO website will inform of 
future updates on this guideline (https://www.eano.eu). 
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Table 1:  Consensus statements and recommendations for the general approach to patients with PCNSL 
including establishment of diagnosis, baseline work-up and response to treatment 
 
Diagnosis 
• Cranial MRI with FLAIR and T1 weighted sequences before and after contrast injection is the 
neuroimaging method of choice for the diagnosis and follow-up of PCNSL. Diffusion, dynamic 
susceptibility contrast, proton spectroscopy MRI, and FDG-PET can be useful in the differential 
diagnosis but are not specific (Good Practice Point).   
• The diagnosis of PCNSL requires pathological confirmation before treatment (Good Practice Point).   
• When PCNSL is suspected, the standard surgical procedure for diagnosis is a stereotactic or navigation 
guided needle biopsy (Good Practice Point, see section on surgery for discussion).   
• Because it may prevent the histopathological diagnosis, it is recommended, if clinically possible, to 
avoid steroids before biopsy. In case of remission and/or unspecific inflammation in the tissue biopsied 
in steroid-pretreated patients, rebiopsy is recommended when close and careful follow-up with serial 
MRI indicates further tumor growth (Good Practice Point).   
• PCNSL are diagnosed according to the WHO classification. Immunohistochemistry is required (Good 
Practice Point, see pathology section in the webappendix).  
• Required immunohistochemical markers for the lymphoma cell characterization should include: pan-B 
cell markers  (CD19,CD20,PAX5), BCL6, MUM1/IRF4, CD10 (Good Practice Point). 
• PCR analysis of immunoglobuline gene families may contribute to diagnosis in difficult cases, in 
particular when inflammatory disorders such as multiple sclerosis or corticosteroid-mitigated PCNSL 
are considered. (Good Practice Point). 
• In case of a suspicion of PCNSL, the work-up should include at least an HIV blood test, a lumbar 
puncture (if not contraindicated) and an ophthalmologic evaluation (with a fundoscopy and a slit lamp 
examination) in all patients, including those without ocular symptoms (Good Practice Point).   
• The identification of lymphoma cells in the CSF or the vitreous may obviate the need for a stereotactic 
brain biopsy to confirm the diagnosis only in the setting of high clinical and radiological suspicion of 
PCNSL. As cytologic diagnosis may be difficult, a review by a specialist pathologist is recommended, 
and in any doubt a brain biopsy is required (Good Practice Point). 
• Immunophenotyping by multiparameter flow cytometry of cells collected in the CSF or vitreous and 
immediately analyzed may add to diagnostic sensitivity. 
•  if B-cell monoclonality is shown in a sample with atypical/suspicious cells. PCR based analysis of 
immunoglobulin gene rearrangement in the CSF reportedly may show false positives. Therefore, 
evidence for the clonality of the lymphocytic cell population considered separately remains insufficient 
for the diagnosis for PCNSL except in case of high clinically documented suspicion of PCNSL (Good 
Practice Point).   
Staging  
• Systemic staging should include: physical examination, CT-scan of the chest, abdomen and pelvis, 
testicular sonography and bone marrow biopsy. FDG body PET may represent an improved alternative 
to total body CT-scan and testicular sonography  (Good Practice Point).  
Prognosis 
• Age and performance status have been consistently identified as treatment-independent prognostic 
factors in PCNSL. Evaluating the individual risk of a PCNSL patient before treatment according to one 
of the existing prognostic scores is recommended (Good Practice Point).   
• Age over 60-65 is used to define the elderly population in PCNSL (Good Practice Point).   
Evaluation of response and follow-up 
• The International Primary CNS Lymphoma Collaborative Group (IPCG) criteria (2005) combining 
MRI, eye examination, CSF analysis and steroid dose should be used to evaluate response to treatment 
(Good Practice Point).  
• There is no evidence as yet that brain FDG PET can be used to assess response in PCNSL in the way 
that it is used for other lymphomas (Good Practice Point). 
• Formal prospective neuropsychometric testing is recommended in the follow-up of patients treated in 
clinical trials on PCNSL (Good Practice Point).   
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Table 2: Consensus statements and recommendations for treatment of patients with PCNSL   
 
Surgery 
• Surgical resection may be considered in patients suffering from a large space occupying lesion with 
acute symptoms of brain herniation to reduce rapidly intracranial pressure (Good practice point). 
• In patients with an unifocal and resectable lesion suspected of PCNSL, no consensus was met in the 
panel to recommend either surgical resection or biopsy 
Chemotherapy 
• CHOP-regimens and derivatives are not indicated in PCNSL (Level B). 
• Chemotherapy should include MTX at HD (≥ 3g/m2) both to cross the BBB and yield cytotoxic levels 
in the CSF. It should be delivered in 2-3 hour iv infusions for a minimum of 4-6 injections and at 
intervals that should not exceed 2-3 weeks (Good Practice Point).   
• Combination of HD-MTX with other chemotherapeutic agents improves the response rates with respect 
to HD-MTX alone (Level B).  
• Chemotherapeutic agents to combine with HD MTX should be selected among active drugs known 
to cross BBB, such as HD cytarabine  (Level B). 
• HD-MTX-chemotherapy is feasible in elderly patients with adequate performance status and renal 
function (Level B). 
• BBBD followed by IA MTX is an alternative experimental approach appropriated for a selected group 
of patients that should be undertaken by trained teams only (Level B). 
• The value of IT chemotherapy as prophylaxis is unclear. IT chemotherapy (intralumbar or preferably 
intraventricular through an Ommaya reservoir) can be proposed in case of documented meningeal 
involvement with insufficient response to iv HD MTX (>3g/ m2) based chemotherapy (Good Practice 
Point).   
• Rituximab combined with a chemotherapy regimen is still an experimental regimen that has its main 
place in clinical trials (Level C). 
Radiotherapy 
• WBRT, HD MTX, and a fortiori combined treatment expose patients to an increased risk of 
neurotoxicity (Level A). 
• The role of consolidation WBRT following HD-MTX based chemotherapy remains debated. In 
addition, the optimal dose is not yet defined, but it should be chosen on the base of response to primary 
chemotherapy (Good Practice Point).   
• In patients with progressive or residual disease after primary chemotherapy, a total dose of 40-45 Gy 
with a 1.8-2 Gy dose /fraction appears advisable. With such doses, there is no evidence to add a focal 
boost on the enhancing lesions (Good Practice Point).   
• In patients < 60 years who have achieved a CR to induction chemotherapy, the option of immediate 
WBRT (40 - 45 Gy in 1.8 - 2.0 Gy fractions) or WBRT omission should be discussed with the patient. 
Reduced dose WBRT consolidation (23.4 - 30 Gy in 1.8 - 2.0 Gy fractions) is a therapeutic option that 
should be investigated in a clinical trial (Good Practice Point).   
• In patients > 60 years, the risk of delayed neurotoxicity, after WBRT  (doses >30 Gy in 1.8-2.0 Gy 
fractions ) especially if following HDMTX , is unacceptably high and WBRT at this dose should be 
deferred or avoided (Level B). 
High dose chemotherapy with autologous stem cell transplantation (HDC/ASCT) 
• HDC/ASCT is an efficient treatment in relapsed or refractory PCNSL (Level B).  
• HDC/ASCT should be reserved for patients < 60-65 years (Good Practice Point).   
• High-dose thiotepa-based conditioning chemotherapy should be preferred over the BEAM regimen 
(Level C).  
• HDC/ASCT as consolidation in first-line treatment remains experimental in PCNSL and should be 
restricted by selected trained centers  (Good Practice Point).   
Primary intraocular lymphoma (PIOL) 
• PIOL may be treated by either HD-MTX-based chemotherapy (with or without WBRT) or by local 
therapy (intravitreal chemotherapy or ocular RT) (Good Practice Point).   
• Local treatment (intravitreal chemotherapy or ocular RT) is a valid approach for patients with systemic 
chemotherapy contraindications or for elderly patients with relapsing intraocular disease (Good Practice 
Point).   
• Concurrent intraocular and CNS lymphoma should be treated no differently from PCNSL (Good 
Practice Point).   
• If consolidation WBRT is proposed, it should include both eyes (Good Practice Point).   
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• Refractory and relapsed IOL should be treated according to the patients’ characteristics and prior 
treatments. Treatments include intravitreal injections of MTX, focal radiotherapy, WBRT, systemic 
chemotherapy and HDC/ASCT (Good Practice Point).  
Salvage treatment 
• Patients with relapsed / refractory PCNSL should be enrolled into phase I-II trials (Good Practice 
Point).   
• The choice of the most appropriate salvage treatment should depend upon the patient’s age, 
performance status, comorbidity, site of relapse, prior therapy, and duration of previous response. The 
expected side effects of the chosen drug must also be considered carefully (Good Practice Point).   
• Salvage WBRT may be proposed in radiotherapy-naïve patients; it may be preceded by induction 
chemotherapy (Good Practice Point) 
• HDC/ASCT is a valid therapeutic option in patients aged <60-65 years with chemosensitive relapsing 
PCNSL (Level B). 
• Salvage chemotherapy can be delivered as induction therapy before WBRT or HDC/ASCT, or as 
exclusive treatment in patients not eligible for these therapies.  
• MTX re-challenge should be considered in recurrent PCNSL patients who previously responded to HD 
MTX (Level C). 
• Isolated extra-CNS relapses should be managed with anthracycline-based chemotherapy followed or not 
by HDC/ASCT (Good Practice Point)  
 
 
 
 21
WEBAPPENDIX 
 
This webappendix summarizes evidences used for EANO`s recommendations for the general approach to 
PCNSL patients with coverage of diagnostic aspects – pathology and genetics, clinical presentation, pathological 
confirmation, neuropathology of corticosteroid-treated PCNSL, cerebrospinal fluid (CSF) analyses, vitreous 
analyses, staging,– as well as prognostic factors, response criteria to treatment, treatment related neurotoxicity 
and treatment of intraocular lymphoma. 
   
Pathology and genetics 
 
PCNSL is a mature B cell lymphoma corresponding to DLBCL of the CNS. Morphologically, haematopoietic 
tumor cells, mostly resembling centroblasts, are scattered throughout the brain tissue and also exhibit a marked 
angiotropism with sheets of tumor cells clustering within and around blood vessel wall. Immunohistochemistry 
is required for the diagnosis. In addition to the expression of pan-B cell markers (CD19, CD20, PAX5), the 
tumor cells of PCNSL are characterized by a BCL6+IRF/MUM1+CD10- immunophenotype with high 
proliferative activity (Ki-67 indexes of 70-90%), together with high expression of the MYC and BCL2 proteins.1-
3
 With rare exception, Epstein-Barr Virus (EBV) is absent from PCNSL of immunocompetent patients. Ongoing 
activity of the germinal center program and blocked terminal B cell differentiation together with pathways 
deregulated by genetic alterations (B cell receptor, toll like receptor, NF-kB pathways) may foster B cell 
activation and brisk proliferation and be of pathogenetic relevance.4-9 Analysis of the molecular landscape of 
PCNSL indicates that aberrant somatic hypermutation which targets several genes (PIM1, TTF, MYC, KLH14, 
OSPL10, SUSD2) may play an important role in the pathogenesis of PCNSL, 9,10 and that alterations in genes of 
role in CNS development may facilitate DLBCL manifestation in the CNS.10 Epigenetic studies revealed 
frequent gene silencing due to CpG island hypermethylation in individual genes including MGMT, CDKN2A, 
and DAPK.11,12 Recurring chromosomal losses affected the 6q, 6p21.32 (HLA locus) and 9p21 (CDKN2A locus) 
regions.5,13  However, to date, no specific molecular genetic signature distinguishes clearly PCNSL from non-
CNS DLBCL, suggesting an important role of the microenvironement in explaining the peculiar behaviour of 
PCNSL. For research, collecting frozen samples and developing a network for PCNSL tumor banks should be 
encouraged. 
 
Diagnosis 
 
Clinical presentation 
Presenting symptoms may include cognitive decline and/or personality changes, focal neurological deficits and 
increased intracranial pressure. Seizures are less frequent (10%). Ocular symptoms, due to an involvement of 
retina, choroid or vitreous, are represented by floaters and/or blurred vision; they can be either isolated (10%) or 
coexist with cerebral symptoms (10-20%). However, up to one-half of patients with PCNSL and ocular 
involvement have no visual symptoms. Insidious onset and delayed diagnosis of intraocular lymphoma are 
common.14 In immunocompetent patients, cranial MRI with contrast enhancement typically shows intense and 
homogeneously enhancing single lesions (70%) or multiple lesions (30%) with  modest surrounding edema, 
usually located in periventricular areas and/or deep gray matter.15,16 Although suggestive, all these MRI findings 
are not specific. Advanced imaging techniques, especially FDG-PET, diffusion tensor imaging, dynamic 
susceptibility contrast MRI (DSC-MRI) and proton MR spectroscopy can increase the diagnostic accuracy and 
help in differentiating PCNSL from other brain tumors or non-tumor lesions.17-26 However, although some 
signatures are highly suggestive of PCNSL, especially when present together (low regional cerebral blood 
volume ratios, high percentage of signal-intensity recovery at the end of the first pass of contrast agent relative to 
baseline, very high lipid resonances), they are not sufficiently specific in practice to replace pathological 
confirmation.   
 
Pathological confirmation  
Diagnosis always needs to be confirmed pathologically, according to the WHO classification in most cases by 
stereotactic needle biopsy.1 In classical cases, combined histology and immunohistochemistry yields the 
diagnosis of PCNSL, i.e. DLBCL of the CNS. In such cases, molecular studies are not required. In equivocal 
cases PCR testing for clonality may aid the diagnosis.27,28  
 
Neuropathology of corticosteroid-treated PCNSL 
As the tumor cells of PCNSL are potentially highly sensitive to corticosteroids, they may undergo rapid 
apoptosis. Transient tumor shrinkage or disappearance of contrast enhancement may occur even after short 
 22
exposure to steroids in approximately 40% of PCNSL, coupled with significant neurological improvement.29  
Stereotactic or navigation guided needle biopsy in this setting may be non-diagnostic in up to 50% of cases.30 In 
the absence of tumor blasts, resorptive changes with prominent infiltration of macrophages, T cells, reactive 
astrocytes , and prominent microglial activation may prevail. In some cases, a few enlarged B cells may persist, 
being suspicious of blast. In such cases, PCR analysis of immunoglobuline genes may demonstrate 
monoclonality. However, a small number of B cells may pretend monoclonality ("pseudoclonality"). Therefore, 
unless patients are rapidly deteriorating with suggestive radiological features of PCNSL, it is usually 
recommended to defer corticosteroids until histologic confirmation has been obtained. Clinicians referring from 
peripheral hospitals should discuss with the specialist neurosurgical centre before starting corticosteroids. If, 
nevertheless, corticosteroids have been given with a subsequent objective response, tapering corticosteroids 
within one or two weeks and delaying biopsy until tumor regrowth would be a reasonable option. Since regrowth 
occur in most cases within a few weeks after discontinuation corticosteroids, a serial MRI follow-up with one 
month interval may be recommended at least the first three months. If no significant changes in contrast 
enhancement or progression are observed, biopsy seems associated with a relatively good probability of yielding 
a diagnosis despite steroid pre-treatment.31  
 
CSF analysis 
The identification of lymphoma cells in the CSF or in a vitreous biopsy, when possible, may obviate the need for 
a brain biopsy for the diagnostic confirmation, only in the setting of high clinical and radiological suspicion of 
PCNSL. Frequently, CSF is characterized by elevated protein levels in 75% and mild pleiocytosis in 50% of 
patients. However, lymphoma cells are detected in only 10-30% in the CSF.32,33 Cellular immunophenotyping by 
flow cytometry in the CSF and PCR analysis of immunoglobulin heavy and light chain genes may help to 
distinguish malignant cells from reactive lymphocytes by identifying clonal B-cell populations even when 
cytological examination is negative.34,35 However, low cell numbers in the CSF sample are frequently found and 
may make flow cytometric analysis difficult. A relatively high ratio of PCR false negatives has been reported in 
PCNSL.33,36 Different CSF molecular genetic markers and proteins including microRNA (miR-21, miR-19b, and 
miR-92),37 soluble CD19,38 antithrombin III,39 free immunoglobulin light chains,40 and interleukin-10 and 
CXCL13,41 are potentially useful diagnostic biomarkers for PCNSL but require further validation before being 
used in routine practice. As cytologic diagnosis may be difficult, in any doubt or inconsistencies with the patient 
clinical setting, a pathological confirmation by a brain biopsy is recommended.  
 
Vitreous analysis 
Ophthalmologic evaluation includes fundoscopy and slit lamp examination. Fluorescein angiography may be 
useful for lymphomatous involvement of the retina.14 Ophthalmologic involvement has to be confirmed by 
vitreous biopsy when eyes are the unique site of disease. Positive cytology is obtained in 70% of cases in trained 
pathology department. As for CSF, immunophenotyping and detection of IgH or T-cell receptor rearrangements 
by PCR analysis indicating monoclonality are helpful tools for diagnosis.42,43 High levels of interleukin 10 
(IL10) and/or high IL10 / IL6 ratio in ocular fluids are strongly suggestive of B-cell lymphomatous uveitis,44 but 
are not diagnostic.  
 
Staging 
The aims of staging are both to specify the extent of the lymphoma within the CNS and to exclude the presence 
of the disease elsewhere. If not contraindicated and already performed at the diagnostic work-up, all patients 
should have a lumbar puncture for CSF cytology.  Systemic involvement is present in up to 12% of the cases.45,46 
Since identification of a systemic site of the lymphoma has important implications for the treatment strategy, an 
international workshop to standardize baseline evaluation recommended performing at least a CT-scan of the 
chest, abdomen and pelvis, a bone marrow biopsy, a testicular ultrasound in elderly males.47 FDG body PET, 
which is more sensitive than the body CT-scan,48is not yet an established routine diagnostic investigation, but is 
used in some European countries as an integral part of diagnostic work-up.   
 
Prognostic factors 
 
Age and performance status have been consistently recognized as the most important therapy-independent 
prognostic factors.49-53 Based on retrospective cohorts of PCNSL, other variables including serum lactate 
dehydrogenase (LDH) levels, involvement of deep brain structures,53-55 CSF protein levels,50,53 and extent of 
lesions within the CNS (multifocal versus unifocal),52 have been correlated with outcome, and some of them are 
integrated with age and performance status in different prognostic scoring systems. Hence, three clinically 
meaningful prognostic scores are available for PCNSL: the IELSG score,53 the MSKCC score,51 and the 
Nottingham-Barcelona score.52 All of them distinguished 3 different risk groups. Using such scoring systems is 
useful to compare studies in order to avoid as much as possible selection biases. Since then, other prognostic 
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factors have been correlated with unfavorable outcome and need to be validated in independent series: elevated 
FDG uptake on PET,56 chromosome 6q deletion or CDKN2A homozygous deletion in the tumor DNA,5,57 and 
delayed response to initial chemotherapy, as compared to early response.58 Several variables have yielded 
opposite results in retrospective studies, such as apparent diffusion coefficient (ADC) value derived from 
diffusion-weighted imaging,59-61BCL-6 expression analysis,62-66 and MTX exposure reflected by MTX area 
under the curve (AUC).67-70  
 
Response criteria  
 
In 2005 the International Primary CNS Lymphoma Collaborative Group (IPCG) published a consensus opinion 
to standardize response criteria and outcome measures in immunocompetent patients with PCNSL.47 These 
response criteria define CR as complete disappearance of contrast enhancement on MRI, no evidence of ocular 
lymphoma, negative CSF cytology and discontinuation of corticosteroid use for at least 2 weeks prior to the 
evaluation of response. Since corticosteroids may mask presence of residual disease its discontinuation is 
included as an essential requirement. The IPCG also delineated which findings are compatible with unconfirmed 
CR (CRu). It is important to sort out CRu from PR because the latter means failure of primary treatment. 
According to the IPCG outline CRu includes those cases who fulfill the criteria for CR with the following 
limitations: at time of evaluation the patient is still on any dose of corticosteroids, MRI continues to show small 
but persistent enhancing abnormalities related to biopsy/surgical site or to focal hemorrhage, and the follow-up 
ophthalmologic examination shows persistent minor abnormality which is unlikely to represent ocular 
lymphoma. PR is defined as 50% decrease in enhancing tumor or residual disease on eye examinations, or 
persistent or suspicious CSF cytology. Progressive disease (PD) is recognized as 25% increase in the enhancing 
lesion or appearance of any new site of disease in the CNS or as systemic disease, recurrent or new ocular 
disease, or recurrent or positive CSF cytology. Of note, these definitions do not take into account the non-
enhancing lesion best visualized on T2-Flair MRI, whose differential diagnosis may be challenging since it could 
be treatment-related white matter changes (including leukoencephalopathy) but also correspond to infiltrative 
PD.71 There no evidence as yet  that brain FDG PET can be used to assess response in PCNSL in the way that it 
is used  for other lymphomas.    
 
Delayed neurotoxicity 
 
Delayed treatment-related neurotoxicity has been systematically evaluated in few studies (Class II and III). 
However, there is a general perception and agreement, that the combination of HD MTX and WBRT is 
associated with disabling neurotoxicity with an incidence of 25% to 35% and related mortality of 30%.50,72 This 
deleterious treatment complication typically occurs several months to years after successful treatment. 
Neuropsychological examination may confirm impaired psychomotor speed, executive function, attention and 
memory.73 Affected patients show cortical/subcortical atrophy and leukoencephalopathy,73-75 which may leave 
them demented, ataxic and incontinent. Median survival after onset of clinically-evident neurotoxicity is less 
than 1-2 years.50,72,75 Autopsy findings include myelin and axonal loss, gliosis, spongiosis, thinning of white 
matter, small and large vessel disease, and necrosis.75,76 Of note, imaging abnormalities may not always correlate 
with the neurologic impairment severity over time. In a retrospective mono-institutional series analysis of 183 
patients, only the administration of WBRT was identified as an independent risk factor for the development of 
late neurotoxicity: in this series, 2% treated with chemotherapy alone developed clinically-evident neurotoxicity, 
while 33% treated with combination chemo-/radiotherapy were affected. The cumulative incidence of 
neurotoxicity for the whole group was 5% at 2 years and 24% at 5 years, with a substantially higher risk in 
patients ≥ 60 years (Class IIIb).75 They are related to clinically and radiologically overt neurotoxicity. The 
prevalence of treatment-related “subtle” cognitive dysfunction amongst patients treated for PCNSL is probably 
largely underestimated as formal psychometric evaluationshave not been routinely performed in most 
prospective studies. Small case series identified WBRT, and not chemotherapy, as the primary cause of 
neurotoxicity in PCNSL.76,77 These results have been confirmed by 3 long-term evaluations (Class IIIb). 78-80 In 
the most recent analysis of 80 long-term survivors of PCNSL, free of tumor and having completed treatment 
with different regimens at least two years prior to evaluation, those who had received WBRT showed 
significantly lower mean scores in attention and executive function, motor skills, and neuropsychological 
composite score, associated with poorer quality of life measures (Class IIIb).80 Moreover, on brain imaging, 
mean areas of total T2 abnormalities in the WBRT group were more than twice the mean of any other non-
WBRT group. These results caution against the routine administration of WBRT as part of upfront treatment and 
call for the implementation of formal neuropsychometric testing in clinical trials on PCNSL.73  
 
Intraocular lymphoma 
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Intraocular infiltration can be the exclusive site of disease at presentation, the so-called primary intra-ocular 
lymphoma (PIOL), or as a part of PCNSL with concomitant brain or meningeal disease. The optimal treatment 
for intraocular lymphoma is not known. Data on therapy and outcome are scarce and limited to retrospective 
case reports or mostly small series with heterogeneous patient populations and treatments. As many as 90 % of 
patients with PIOL patients consequently develop brain involvement over the course of the disease and 
dissemination to the brain is the main cause of death.14,81 The median survival of isolated PIOL is approximately 
60 months.81,82 Treatment may be focal, including ocular RT (historically, total dose of 35-40 Gy, 2 Gy per 
fraction using opposed lateral beams to include both globes) (Class IV) and intravitreal chemotherapy. 83-86 
Uncontrolled series have reported clinical remission with repeated intravitreal MTX and more recently after 
rituximab injections (Class IV).85,86 Treatment may be also extensive, including systemic chemotherapy and 
WBRT. Intraocular responses have been reported with HD MTX,87 HD cytarabine,88,89 ifosfamide, trofosfamide 
used as single agent,90 with MTX-based polychemotherapy and after HDC/ASCT (Class IV).91 A large 
retrospective multicenter study did not show any difference in PIOL between focal and extensive therapy in 
terms of disease control and survival (Class IIIb).81 Unfortunately, this and other studies failed to provide reliable 
predictors of brain dissemination in PIOL patients; thus, some experts recommend local therapy for disease 
confined to the eyes, but others consider that initial treatment of PIOL should not differ from that of PCNSL i.e. 
high-dose MTX-based polychemotherapy followed, or not, by WBRT in order to eradicate possible concomitant 
microscopic disease in the brain and in the CSF responsible for relapse. In this case, local treatments would 
remain options for refractory or recurrent disease confined to the eyes. The management decision should take 
into account the individual risk of treatment toxicities (including those related to ocular treatment)  and local 
expertise.14,92 When intraocular lymphoma is concurrent with brain lesions, it has not been identified as an 
independent prognostic factor and the prognosis is similar to that of the PCNSL without intraocular disease 
(Class IIIb).93 Accordingly, patients with concomitant intraocular and cerebral disease should be treated no 
differently from PCNSL. The value of additional local ocular treatment (i.e. intravitreal chemotherapy or ocular 
radiotherapy if WBRT has not been delivered) to systemic chemotherapy remains matter of debate, with 
conflicting results in two retrospective studies (Class IIIb). 93,94 
 
 
References 
 
 
1. Kluin PM, Deckert M, Ferry JA. Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow SH, 
Campo E, Harris NL, editors. World Health Organisation Classification of Tumours Pathology and 
Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2008; 240–41.  
2. Camilleri-Broet S, Criniere E, Broet P, et al. A uniform activated Bcell- like immunophenotype might 
explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 
2006; 107: 190–96. 
3. Brunn A, Nagel I, Montesinos-Rongen M et al. Frequent triple-hit expression of MYC, BCL2, and BCL6 
in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) 
subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. 
Acta Neuropathol 2013; 126:603-05 
4. Deckert M, Montesinos-Rongen M, Brunn A, et al. Systems biology of primary CNS lymphoma: from 
genetic aberrations to modeling in mice. Acta Neuropathol. 2014 ;127:175-88 
5. Gonzalez-Aguilar A, Idbaih A, Boisselier B, et al. Recurrent mutations of MYD88 and TBL1XR1 in 
primary central nervous system lymphomas. Clin. Cancer Res. 2012;18:5203–5211 
6. Montesinos-Rongen M, Godlewska E, Brunn A, et al. Activating L265P mutations of the MYD88 gene 
are common in primary central nervous system lymphoma. Acta Neuropathol 2011;122:791–92 
7. Montesinos-Rongen M, Schäfer E, Siebert R, et al.. Genes regulating the B cell receptor pathway are 
recurrently mutated in primary central nervous system lymphoma. Acta Neuropathol 2012;124:905–06. 
8. Montesinos-Rongen M, Schmitz R, Brunn A, et al. Mutations of CARD11 but not TNFAIP3 may activate 
the NF-kappaB pathway in primary CNS lymphoma. Acta Neuropathol. 2010;120:529–35. 
9. Bruno A, Boisselier B, Labreche K, et al. Mutational analysis of primary central nervous system 
lymphoma. Oncotarget 2014;5:5065-75 
10. Vater I, Montesinos-Rongen M, Schlesner M et al. The mutational pattern of primary lymphoma of the 
central nervous system determined by whole-exome sequencing. Leukemia 2014.doi: 
10.1038/leu.2014.264 
11. Chu LC, Eberhart CG, Grossman SA, et al. Epigenetic silencing of multiple genes in primary CNS 
lymphoma. Int J Cancer 2006; 119: 2487–91. 
 25
12. Ferreri AJ, Dell’Oro S, Capello D, et al. Aberrant methylation in the promoter region of the reduced 
folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous 
system lymphomas. Br J Haematol 2004; 126: 657–64. 
13. Braggio E, McPhail ER, Macon W, et al. Primary central nervous system lymphomas: a validation study 
of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor 
specimens. Cancer Res. 2011;17:4245–53 
14. Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an 
International Primary Central Nervous System Lymphoma  Collaborative Group symposium. Oncologist. 
2011;16:1589-99 
15. Bühring U, Herrlinger U, Krings T et al. MRI features of primary central nervous system lymphomas at 
presentation. Neurology 2001;57:393–96 
16. Kuker W, Nagele T, Korfel A, et al: Primary central nervous system lymphomas (PCNSL): MRI features 
at presentation in 100 patients. J Neurooncol 2005; 72:169-77 
17. Kawai N, Okubo S, Miyake K, et al. Use of PET in the diagnosis of primary CNS lymphoma in patients 
with atypical MR findings. Ann Nucl Med. 2010; 24:335-43 
18. Yamashita K, Yoshiura T, Hiwatashi A, et al. Differentiating primary CNS lymphoma from glioblastoma 
multiforme: assessment using arterial spin labeling,diffusion-weighted imaging, and ¹⁸F-
fluorodeoxyglucose positron emission tomography. Neuroradiology. 2013; 55:135-43 
19. Toh CH, Castillo M, Wong AM,et al.. Primary cerebral lymphoma and glioblastoma multiforme: 
differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR. 2008;29:471-75 
20. Mangla R, Kolar B, Zhu T, et al. Percentage signal recovery derived from MR dynamic susceptibility 
contrast imaging is useful to differentiate common enhancing malignant lesions of the brain. AJNR 
2011;32:1004-10 
21. Radbruch A, Wiestler B, Kramp L,et al. Differentiation of glioblastoma and primary CNS lymphomas 
using susceptibility weighted imaging. Eur J Radiol. 2013;82:552-56. 
22. Blasel S, Jurcoane A, Bähr O, Weise L, et al. MR perfusion in and around the contrast-enhancement of 
primary CNS lymphomas. J Neurooncol. 2013;114:127-34. 
23. Toh CH, Wei KC, Chang CN, et al. Differentiation of primary central nervous system lymphomas and 
glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced 
perfusion MR imaging without and with contrast-leakage correction.  AJNR 2013 ;34:1145-49 
24. Kickingereder P, Sahm F, Wiestler B, et al. Evaluation of Microvascular Permeability with Dynamic 
Contrast-Enhanced MRI for the Differentiation of Primary CNS Lymphoma and Glioblastoma: 
Radiologic-Pathologic Correlation. AJNR 2014;35:1503-08 
25. Chawla S, Zhang Y, Wang S, et al. Proton magnetic resonance spectroscopy in differentiating 
glioblastomas from primary cerebral lymphomas and brain metastases. J Comput Assist Tomogr 
2010;34:836-41 
26. Lu SS, Kim SJ, Kim HS, et al. Utility of proton MR spectroscopy for differentiating typical and atypical 
primary central nervous system lymphomas from tumefactive demyelinating lesions. AJNR 2014; 
35:270-77 
27. Shaw A, Iyer V, Rooney N, et al. Diagnosis of primary cerebral lymphomas: possible value of PCR 
testing in equivocal cases requiring rebiopsy. Br J Neurosurg 2014: 28:214-19 
28. Deckert M, Brunn A, Montesinos-Rongen M et al. Primary lymphoma of the central nervous system--a 
diagnostic challenge. Hematol Oncol 2014;32:57-67 
29. Pirotte B, Levivier M, Goldman et al. Glucocorticoid-induced long-term remission in primary cerebral 
lymphoma: case report and review of the literature. J Neurooncol. 1997;32:63-69 
30. Brück W, Brunn A, Klapper W et al. Differential diagnosis of lymphoid infiltrates in the central nervous 
system: experience of the Network Lymphomas and Lymphomatoid Lesions in the nervous system. 
Pathologe 2013;34:186-97 
31. Porter AB, Giannini C, Kaufmann T, et al. Primary central nervous system lymphoma can be 
histologically diagnosed after previous corticosteroid use: a pilot study to determine whether 
corticosteroids prevent the diagnosis of primary central nervous system lymphoma. Ann Neurol 
2008;63:662-67 
32. Balmaceda C, Gaynor JJ, Sun M, et al. Leptomeningeal tumour in primary central nervous system 
lymphoma: Recognition, significance, and implications. Ann Neurol 1995;38:202-09. 
33. Korfel A, Weller M, Martus P, et al. Prognostic impact of meningeal dissemination in primary CNS 
lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. Ann Oncol 2013;23:2374-80 
34. Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow 
cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system 
involvement: the role of flow cytometry versus cytology. Blood 2005; 105:496-502 
 26
35. Schroers R, Baraniskin A, Heute C, et al.. Diagnosis of leptomeningeal disease in diffuse large B-cell 
lymphomas of the central nervous system by flow cytometry and cytopathology. Eur J Haematol. 
2010;85:520-28 
36. Fischer, L., Martus, P., Weller, M., et al. Meningeal dissemination in primary CNS lymphoma: 
prospective evaluation of 282 patients. Neurology 2008, 71,1102–08. 
37. Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as 
marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 2011;117:3140-
46. 
38. Muñiz C, Martín-Martín L, López A, et al. Spanish Group for the Study of Central Nervous System 
Disease in Non-Hodgkin Lymphoma. Contribution of cerebrospinal fluid sCD19 levels to the detection 
of CNS lymphoma and its impact on disease outcome. Blood 2014; 123:1864-69 
39. Roy S, Josephson SA, Fridlyand, J, et al. Protein biomarker  identification in the CSF of patients with 
CNS lymphoma. J Clin Oncol 2008, 26,:96–105. 
40. Schroers, R., Baraniskin, A., Heute, C, et al. Detection of free immunoglobulin light chains in 
cerebrospinal fluids of patients with central nervous system lymphomas. Eur J Haematol  2010; 85: 236–
42. 
41. Rubenstein JL, Wong VS, Kadoch C, et al. CXCL13 plus interleukin 10 is highly specific for the 
diagnosis of CNS lymphoma. Blood. 2013 6;121:4740-48. 
42. Shen DF, Zhuang Z, LeHoang P et al. Utility of microdissection and polymerase chain reaction for the 
detection of immunoglobulin gene rearrangement and translocation in primary intraocular lymphoma. 
Ophthalmology 1998;105:1664 –69. 
43. Misotten T,  Tielemans D, Bromberg JE et al.  Multicolor flowcytometric immunophenotyping is a 
valuable tool for detection of intraocular lymphoma. Ophtalmology 2013;120:991-96 
44. Cassoux N, Giron A, Bodaghi B et al. IL-10 measurement in aqueous humor for screening patients with 
suspicion of primary intraocular lymphoma. Invest Ophthalmol Vis Sci 2007;48:3253–59 
45. O’Neill BP, Dinapoli RP, Kurtin PJ, et al. Occult systemic non-Hodgkin’s lymphoma in patients initially 
diagnosed as primary central nervous system lymphoma: How much staging is enough? J Neurooncol 
1995;25:67-71. 
46. Ferreri AJ, Reni M, Zoldan MC, et al. Importance of complete staging in non-Hodgkin’s lymphoma 
presenting as a cerebral mass lesion. Cancer 1996;77:827-33. 
47. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline 
evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034-43. 
48. Mohile NA, Deangelis LM, Abrey LE. Utility of brain FDG-PET in primary CNS lymphoma. Clin Adv 
Hematol Oncol. 2008; 6 :818-20 
49. Corry J, et al. Primary central nervous system lymphoma: age and performance status are more important 
than treatment modality. Int J Radiat Oncol Biol Phys. 1998;41:615-20. 
50. Blay JY, Conroy T, Chevreau C, et al et al. High-dose methotrexate for the treatment of primary cerebral 
lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 
16:864-71. 
51. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial 
Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006 ;24:5711-15. 
52. Bessell EM, Graus F, Lopez-Guillermo A et al. Primary non-Hodgkin’s lymphoma of the CNS treated 
with CHOD/BVAM or BVAM chemotherapy before radiotherapy: Long-term survival and prognostic 
factors. Int J Radiat Oncol Biol Phys 2004;59:501–08. 
53. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the 
International Extranodal Lymphoma Study Group experience. J Clin Oncol.2003 ;21:266-72 
54. Ghesquières H, Drouet Y, Sunyach MP, et al. Evidence of time-dependent prognostic factors predicting 
early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients. Hematol Oncol 
2013;31:317-24 
55. Iwadate Y, Suganami A, Ikegami S, et al. Non-deep-seated primary CNS lymphoma: therapeutic 
responses and a molecular signature. J Neurooncol.2014 ; 117:261-68 
56. Kasenda B, Haug V, Schorb E, et al. 18F-FDG PET is an independent outcome predictor in primary 
central nervous system lymphoma. J Nucl Med 2013;54:184-91. 
57. Cady FM, O’Neill BP, Law ME, et al. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma 
are indicators of an aggressive clinical course. J Clin Oncol 2008;26:4814-19. 
58. Pels H, Juergens A, Schirgens I, et al. Early complete response during chemotherapy predicts favorable 
outcome in patients with primary CNS lymphoma. Neuro Oncol 2010;12:720-24. 
59. Barajas RF Jr., Rubenstein JL, Chang JS, et al. Diffusion weighted MR imaging derived apparent 
diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. 
AJNR 2010;31:60–66. 
 27
60. Wieduwilt M, Valles F, Issa S et al. Immunochemotherapy with intensive consolidation for primary CNS 
lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res 2012; 
18: 1146-55 
61. Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine 
followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed 
primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31:3971-79 
62. Braaten KM, Betensky RA, de Leval L, et al. BCL-6 expression predicts improved survival in patients 
with primary central nervous system lymphoma. Clin Cancer Res 2003; 9: 1063–69. 
63. Levy O, Deangelis LM, Filippa DA, et al. Bcl-6 predicts improved prognosis in primary central nervous 
system lymphoma. Cancer 2008; 112: 151–56. 
64. Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in 
patients with diffuse large B-cell lymphoma. Blood 2001; 98: 945–51. 
65. Preusser M, Woehrer A, Koperek O, et al. Primary central nervous system lymphoma: a 
clinicopathological study of 75 cases. Pathology 2010;42:547-52. 
66. Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, et al. Intensive chemotherapy 
and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 
50202). J Clin Oncol 2013 ;31:3061-68 
67. Ferreri AJ, Guerra E, Regazzi M, et al. Area under the curve ofmethotrexate and creatinine clearance are 
outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004;90: 353–58. 
68. Joerger M, Huitema AD, Krahenbuhl S, et al. Methotrexate area under the curve is an important outcome 
predictor in patients with primary CNS lymphoma: pharmacokinetic pharmacodynamic analysis from the 
IELSG no. 20 trial. Br J Cancer 2010;102:673–77. 
69. Blasco H, Senecal D, Le Gouge A, et al. Influence of methotrexate exposure on outcome in patients 
treated with MBVP chemotherapy for primary central nervous system lymphoma. Br J Clin Pharmacol 
2010;70:367–75. 
70. Morris PG,  Abrey LE, Reiner  AS, et al. Methotrexate area under the curve as a prognostic factor in 
primary CNS lymphoma treated with immunochemoradiotherapy. Leuk Lymphoma, 2011;52:1891-97 
71. Fischer L, Koch A, Schlegel U, et al. Non-enhancing relapse of a primary CNS lymphoma with multiple 
diffusion-restricted lesions. J Neurooncol 2011;102:163-66. 
72. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 
1998; 16:859-63 
73. Correa DD, Maron L, Harder H, et al. Cognitive functions in primary central nervous system lymphoma: 
literature review and assessment guidelines. Ann Oncol 2007; 18:1145-51 
74. Wassenberg MW, Bromberg JE, Witkamp TD et al. White matter lesions and encephalopathy in patients 
treated for primary central nervous system lymphoma. J Neurooncol 2001; 52:73-80 
75. Omuro AM, Ben-Porat LS, Panageas KS et al. Delayed neurotoxicity in primary central nervous system 
lymphoma. Arch Neurol 2005; 62:1595–600 
76. Harder H, Holtel H, Bromberg JEC et al. Cognitive status and quality of life after treatment for primary 
CNS lymphoma. Neurology 2004;62:544-47 
77. Correa DD, DeAngelis LM, Shi W. et al. Cognitive functions  in survivors of primary central nervous 
system lymphoma. Neurology 2004;62:548-55 
78. Jürgens A, Pels H, Rogowski S, et al. Long-term survival with favorable cognitive outcome after 
chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010;67:182-89. 
79. Correa DD, Shi W, Abrey LE, DeAngelis LM, et al. Cognitive functions in primary CNS lymphoma after 
single or combined modality regimens. Neuro Oncol 2012; 14:101-08. 
80. Doolittle ND, Korfel A, Lubow MA, et al. Long-term cognitive function, neuroimaging, and quality of 
life in primary CNS lymphoma. Neurology 2013; 81:84-92 
81. Grimm SA, Pulido JS, Jahnke K, Schiff D, et al. Primary intraocular lymphoma: an International Primary 
Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 2007 ;18:1851-55. 
82. Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. Ocular presentation of primarycentral nervous 
system lymphoma: diagnosis and treatment. Br J Haematol 2004;126:202-08 
83. Margolis L, Fraser R, Lichter A, et al.. The role of radiation therapy in the management of ocular 
reticulum cell sarcoma. Cancer. 1980;45:688-92 
84. Berenbom A, Davila RM, Lin HS, et al. Treatment outcomes for primary intraocular lymphoma: 
implications for external beam radiotherapy. Eye  2007;21:1198-201 
85. Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 
years of experience. Br J Ophthalmol 2008;92:383-88 
86. Hashida N, Ohguro N, Nishida K. Efficacy and Complications of Intravitreal Rituximab Injection for 
Treating Primary Vitreoretinal Lymphoma.Transl Vis Sci Technol 2012; 1:1-11 
Formatted: Bullets and Numbering
 28
87. Batchelor TT, Kolak G, Ciordia R, et al. High-dose methotrexate for intraocular lymphoma. Clin Cancer 
Res 2003;9:711-15. 
88. Siegel MJ, Dalton J, Friedman AH, et al. Ten-year experience with primary ocular 'reticulum cell 
sarcoma' (large cell non-Hodgkin's lymphoma). Br J Ophthalmol 1989;73:342-46. 
89. Strauchen JA, Dalton J, Friedman AH. Chemotherapy in the management of intraocular lymphoma. 
Cancer 1989;63:1918-21 
90. Jahnke K, Thiel E, Bechrakis NE, Willerding G, et al. Ifosfamide or trofosfamide in patients with 
intraocular lymphoma. J Neurooncol 2009 ;93:213-17 
91. Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by 
haematopoietic stem cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or 
intraocular lymphoma. J Clin Oncol 2001; 19:742-49. 
92. Rajagopal R, Harbour JW. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma. 
Retina 2011;31:435–40  
93. Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: 
International PCNSL Collaborative Group Report. Neurology 2008 ;71:1355-60 
94. Ferreri AJ, Blay JY, Reni M, et al. International Extranodal Lymphoma Study Group (IELSG). 
Relevance of intraocular involvement in the management of primary central nervous system lymphomas. 
Ann Oncol 2002;13:531-38 
 
 
 1
 
EANO Guideline for the diagnosis and treatment of primary CNS lymphoma in immunocompetent 
patients. 
 
Prof Khê Hoang-Xuan MD (1), Eric Bessell FRCR (2), Jacoline Bromberg MD (3), Andreas F. 
Hottinger MD (4), Matthias Preusser MD (5), Roberta Rudà MD (6), Prof Uwe Schlegel MD (7), Prof 
Tali Siegal MD (8), Carole Soussain MD (9), Ufuk Abacioglu MD (10), Nathalie Cassoux MD (11), 
Prof Martina Deckert MD (12), Prof Clemens M.F.Dirven MD (13), Andrés J.M. Ferreri MD (14), 
Francesc Graus MD (15), Prof Roger Henriksson MD (16), Ulrich Herrlinger MD (17), Prof Martin 
Taphoorn MD (18), Prof Riccardo Soffietti MD (6), Prof Michael Weller MD (19) for the European 
Association for Neuro-Oncology (EANO) Task Force on Primary CNS Lymphoma 
 
 
(1) APHP, Department of Neurology Mazarin, Hôpital Pitié-Salpêtrière; Sorbonne Universités, 
UPMC; IHU; ICM; LOC network-INCa. 47 Bld de l’Hôpital. 75013 Paris, France    
(2) Department of Clinical Oncology, Nottingham City Hospital , Nottingham , NG5 1PB, United 
Kingdom 
(3) Department of Neuro-Oncology, , Erasmus MC Cancer Institute, University Medical Center, 
Groene Hilledijk 301, 3075EA, Rotterdam. The Netherlands 
(4) Departments of Neurology & Oncology, Centre hospitalier universitaire Vaudois and University of 
Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland 
 (5) Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, 
Spitalgasse 23, 1090, Vienna, Austria 
(6) Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, Via 
Cherasco 15 - 10126 Torino, Italy 
(7) Department of Neurology University Hospital Bochum, Knappschaftskrankenhaus. In der 
Schornau 23 – 25 D-44892 Bochum  
(8) Center for Neuro-Oncology, Davidoff Institute of Oncology, Rabin Medical Center, Campus 
Beilinson, Petach Tikva 49100, Israel  
(9) Hematology department, Hôpital René Huguenin - Institut Curie, Saint-Cloud, Paris and Collège 
de France, CNRS UMR 7241/INSERM U1050, Paris,France 
(10) Neolife Medical Center Radiation Oncology Department. Nisbetiye mah. Yucel sokak 6 Besiktas, 
Istanbul, Turkey 
(11) Department of Ophtalmology, Institut Curie, 26 rue d’Ulm, 75005 Paris, France 
(12) Department of Neuropathology, University of Cologne, Kerpener Strasse 62, Cologne D-50924 
Germany 
(13) Department of Neurosurgery, Brain Tumor Center,  Erasmus MC Cancer Institute, Rotterdam , 
The Netherlands  
(14) Unit of Lymphoid Malignancies a Division of Onco-hematological Medicine, Department of 
Onco-hematology, IRCCS San Raffaele Scientific Institute. Via Olgettina 60. 20132 - Milano, Italia 
(15) Department of Neurology of Hospital clinic, Villarroel 170, 08036 Barcelona, Spain 
(16) Regional Cancer Center Stockholm County, Box 6909, SE-102 39 Stockholm, and Department of 
Radiation Sciences & Oncology, Umeå University, S-901 87 Umea, Sweden  
(17) Division of Clinical Neuro-Oncology, Department of Neurology, University of Bonn Medical 
Center, Sigmund-Freud-Straße 25, 53127 Bonn, Germany 
(18) Department of Neurology, Medical Center Haaglanden, PO Box 432, 2501 CK The Hague and 
Department of Neurology, VU University Medical Center Amsterdam, The Netherlands 
(19) Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, CH-8091 Zurich, 
Switzerland 
 
Corresponding author: Khê Hoang-Xuan, MD, PhD, Department of Neurology Mazarin, Hôpital Pitié-
Salpêtrière; 47 Bld de l’hôpital, Paris 75013, France. email: khe.hoang-xuan@psl.aphp.fr 
*Manuscript
 2
 
Abstract 
 
The management of primary central nervous system (PCNSL) is one of the most controversial topics 
in neuro-oncology because of the complexity of the disease and the very limited number of controlled 
studies available. In 2013, the European Association of Neuro-Oncology (EANO) created a 
multidisciplinary task force to establish evidence-based guidelines for immunocompetent adult 
patients with PCNSL. The guideline provides consensus considerations and recommendations for 
diagnosis, staging and treatment of PCNSL, including surgery, systemic and intrathecal chemotherapy, 
intensive chemotherapy with autologous stem cell transplantation, radiotherapy, intraocular 
manifestations, and specific management of elderly patients. The guideline should aid the clinicians in 
everyday practice and decision making and serve as a basis for future research in the field. 
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Introduction 
 
Primary central nervous system lymphomas (PCNSL) are extranodal malignant non-Hodgkin 
lymphomas (NHL) of the diffuse large B cell (DLBCL) type confined to the brain, eyes, 
leptomeninges, or spinal cord in the absence of systemic lymphoma. Currently PCNSL are estimated 
to account for up to 1% of lymphomas, 4-6% of all extranodal lymphomas, and about 3% of all CNS 
tumors.1 After a continuous increase in the 1980’s and 1990’s, epidemiologic data in Western 
countries show a decrease in the incidence of PCNSL, particularly among young patients suffering 
from AIDS.2 In contrast, the incidence continues intriguingly to rise in the elderly who represent 
consequently the large majority of patients in the immunocompetent population in some recent 
studies.3-5 Although the prognosis of PCNSL remains poor, it has significantly improved over the past 
two decades as a result of better treatment strategies with a curative aim. Treatment of PCNSL is 
challenging. Despite a high chemosensitivity and radiosensitivity, remissions are frequently short-
lasting; the blood brain-barrier (BBB) limits the access of many drugs to the CNS; and patients, 
especially the elderly, are at high risk of developing severe treatment related-neurotoxicity. To date, 
therapeutic knowledge to define the optimal treatment mainly results from retrospective series or 
single arm phase II studies, with only three completed randomized trials available: one phase III and 
two phase II. The objective of this guideline is to provide clinicians with evidence-based 
recommendations and consensus expert opinions on the management of patients with PCNSL. The 
present guideline focuses on the immunocompetent population which represents the vast majority of 
the patients today. PCNSL of immunodeficient patients and the rare indolent low grade lymphomas 
occurring primarily in the CNS, which have a distinct pathogenesis with separate diagnostic and 
therapeutic implications, will be subject to specific guidelines.  
 
Search strategy and selection criteria  
 
The guideline task force was set up in 2013 under the auspices of the EANO (European Assocation for 
Neuro-Oncology) and selected to be representative of European-based medical experts (10 countries). 
The panel covered all fields of expertise in the management of PCNSL, i.e. neurologists, 
haematologists, medical oncologists, neurosurgeons, pathologists, ophthalmologists and radiation 
oncologists. Based on best available evidence from literature review, the writing group (EB, JB, AH, 
KHX, MP, RR, US, TS, CS) produced the draft guideline, which was subsequently submitted to the 
review committee (UA, NC, MD, CD, AF, FG, RH, UH, RS, MT, MW). The revised guideline, taking 
into account the comments of the reviewers, was resubmitted by the chairman to the whole task force 
for review and amendments twice. Therafter, final agreement was obtained in September 2014. When 
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analyzing results and drawing recommendations, at any stage, differences were resolved by 
discussiondiscussion and, if persisting, were reported in the text. References for this review were 
identified through searches of PubMed with the search terms ”primary CNS lymphoma”,”primary 
central nervous system lymphoma”, “primary intraocular lymphoma”, “elderly”, “radiotherapy”, 
“chemotherapy” and “rituximab” from January 1980 to September 2014. Articles were also identified 
through searches of the authors` own files. The final reference list was generated on the basis of 
originality and relevance to the broad scope of this review. Abstracts presented at the annual ASCO 
meeting in 2013 and 2014 relevant to the topic were included by task force members during 
manuscript preparation. The scientific evidence of papers collected from the literature was evaluated 
and graded as follows and recommendations were given accordingly. Class I evidence was derived 
from prospective, randomized, phase III clinical trials; class IIa evidence was derived from prospective 
randomized phase II trials, class IIb evidence was derived from phase II trials; class IIIa was derived 
from prospective studies, including observational studies, cohort studies and case–control studies; 
class IIIb evidence was derived from retrospective studies; class IV evidence was derived from 
uncontrolled case series, case reports and expert opinion. As for recommendations, level A required at 
least one class I study or two consistent class IIa studies, level B at least one class IIa study or 
overwhelming class IIb and III evidence and level C at least two consistent class III studies. 
Pathology, genetics, clinical features and neuroimaging were simply reviewed but not graded. When 
suﬃcient evidence for recommendations A–C was not available, we gave a recommendation as a 
“Good Practice Point”, if agreed by all members of the Task Force.  
 
General recommendations 
 
Consensus statements and recommendations for the general approach to patients with PCNSL, 
including: 1/ pathology and genetics, 2/ clinical presentation, 3/ diagnostic confirmation, 4/ 
neuropathology of corticosteroid-treated PCNSL, 5/ neuroimaging, 6/ cerebrospinal fluid (CSF) 
analyses,  7/ vitreous analyses, 8/ staging, 9/ prognostic factors, 10/ response criteria to treatment, and 
11/ treatment-related neurotoxicity are presented in table 1. The evidences used to establish these 
recommendations are detailed in the supplementary webappendix. Key recommendations for treatment 
are summarized in table 2. The evidences concerning intraocular lymphoma are presented in the 
webappendix.  Our guideline covers treatment of histologically or cytologically proven PCNSL. We 
have not covered specifically the treatment of patients with deep seated tumours not readily amenable 
to biopsy for which there are no evidence-based recommendations. We believe that biopsies are almost 
always possible in specialized centers and that chemotherapy and/or  radiotherapy interventions 
without histological confirmation of PCNSL should be discouraged.  
 
 Surgery 
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Although very few data are available in the literature, surgery has traditionally been considered to 
have no role in the treatment of PCNSL. This widely adopted opinion is based on small retrospective 
series suggesting no clear benefit in outcome of surgical resection used as sole treatment compared 
with supportive care (Class IIIb),6 and compared with biopsy in patients having received post-
operative chemotherapy and/or radiotherapy (Class IIIb).7,8 This may be explained by the 
microscopically multifocal and infiltrative nature of PCNSL that may extend beyond the visible border 
of the lesion.9 The relative radiosensitivity and high chemosensitivity of PCNSL, and the increased 
risks of postoperative morbidity of this patient population have also contributed to discourage surgery. 
However, the recommendation to restrict surgical interventions to biopsies is not based on randomized 
data and, more importantly, not on contemporary data reflecting modern neurosurgery. The German 
PCNSL Study Group–1 phase III trial included an unusually high rate of operated patients, which 
allowed the largest and most recent retrospective analysis of an association of surgery and outcome. A 
significantly longer progression free survival (PFS) and overall survival (OS) in patients with subtotal 
or gross total resections compared with biopsied patients was reported. This difference in outcome was 
independent of post-operative Karnofsky performance status (KPS) and age. Since biopsied patients 
more often had multiple and/or deeply seated CNS lesions than resected patients, these features may 
have contributed to the unfavourable outcome. When adjusted for the number of lesions (site of the 
lesions was not analyzed in the study), the difference in outcome remained significant in term of PFS 
but did not reach the significance threshold for OS (Class IIIa).10  
 
Systemic chemotherapy 
The CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) regimen commonly used for 
systemic NHL induces short-lasting responses in PCNSL and its addition to radiotherapy has not 
shown a survival benefit in prospective trials (Class IIb).11-13 This inefficacy is probably due to the fact 
that phosphoramide mustard and doxorubicin are not able to cross the blood-brain barrier (BBB) to 
eradicate microscopic disease. Based on convergent results from numerous prospective and 
retrospective studies, high-dose (HD) intravenous (iv) methotrexate (MTX), an antifolate and 
antimetabolite, is now considered the most important and beneficial single agent. Penetration of MTX 
into the CNS depends both on the total dose and rate of infusion. The optimal dose of MTX has not 
been determined. It has been estimated that the iv MTX should range between 1 g/m2 and 8 g/m2 to 
cross the BBB. In the absence of clear evidence for dose-response relationship, and since rapid 
infusion of MTX ≥ 3g/m2 over 3 hours achieves cytotoxic levels in the CSF, there is a growing 
consensus to deliver MTX according to this protocol (Class IV).14 Since efficacy of MTX may also 
depend on duration of exposure, MTX administration interval should range between 10 days and 3 
weeks (Class IV).15 The optimal number of MTX injections to deliver is unknown. A minimum of 4-6 
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injections is delivered in most chemotherapy regimens, especially if no consolidation treatment 
(radiotherapy and/or intensive chemotherapy) is scheduled in the protocol. For patients who achieved 
only partial response (PR) after 4-5 courses of HD MTX, additional courses may improve the 
complete remission rate (Class IIIa).16 Infusions of HD MTX require pre- and post-hyperhydration, 
urine alkalinization, leucovorin rescue and MTX concentration monitoring. Currently most treatment 
protocols combine HD MTX with a variety of other chemotherapeutic agents to improve response rate 
and outcome. The best evidence to support this approach comes from an IELSG randomized phase II 
study comparing HD MTX alone, administered at 3 g/m2/d every 21 days, to HD MTX with 
cytarabine (2 g/m2 twice per day on days 2–3)(Class IIa).17 Both chemotherapy arms were followed by 
WBRT. This study showed a significantly higher complete response (CR) rate in the HD MTX-
cytarabine arm. Regarding secondary endpoints, a significantly improved overall response rate (ORR), 
PFS and a trend towards better OS in the HD MTX-cytarabine arm were noticed. Two previous 
prospective trials evaluating HD MTX at a dose of 8g/m2 as single agent and without immediate 
consolidation WBRT resulted in a shorter PFS when compared to polychemotherapy regimens (Class 
IIb).18,19 Similarly, the addition of ifosfamide to HD-MTX improved response rate, but not survival, in 
the G-PCNSL-SG-1 trial.20 Altogether, these data resulted in the recognition that only HD MTX can be 
defined as a chemotherapy standard of care.21 Chemotherapeutic agents to be combined with HD MTX 
should be selected among active drugs known to cross the BBB, such as HD cytarabine. Recently, the 
CALGB50202 multicenter phase II trial reported promising results using HD cytarabine combined 
with etoposide as consolidation without WBRT following a HD MTX-based polychemotherapy as 
induction regimen (Class IIb).22 In contrast, very disappointing results have been reported in a pilot 
study combining HD MTX (3.5g/m2), thiotepa and cytarabine at a reduced dose of 1g/m2 suggesting 
that the cytarabine dose probably was suboptimal to reach cytototoxic levels in the CNS (Class IIIa),23 
as supported by pharmacokinetic studies.24 Another approach is BBB disruption (BBBD) by intra-
arterial (IA) infusion of hypertonic mannitol followed by intra-arterial (IA) chemotherapy to increase 
the drug concentration in the CNS. BBBD with IA MTX administrated in newly diagnosed PCNSL 
demonstrated a good safety profile and neurocognitive tolerance and achieved comparable outcomes 
to those observed with HD-intravenous MTX based chemotherapy regimens (Class IIIb).25-27 
However, conversely to those reported in prospective studies on chemoradiotherapy, even after a 
follow-up longer than 10 years (Class IIb),28 BBBD is not associated with a plateau in survival curves, 
suggesting a continuum of relapses and deaths. This procedure requires patient selection as safety 
depends on the extent of intracranial mass effect and the procedure is limited to patients with no 
contraindications for general anesthesia. It should be managed by teams trained in BBBD as it is 
complex, requiring cannulation of the intracranial vessels. In summary, HD MTX is the drug of choice 
for PCNSL. In patients who are not eligible for HD MTX, treatment should be chosen from treatments 
active as salvage in refractory or recurrent PCNSL after initial HD MTX based chemotherapy (see 
salvage treatment section).   
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Intrathecal chemotherapy 
 
Intrathecal (IT) chemotherapy administration has not been prospectively studied and its efficacy in 
PCNSL remains debated. Three retrospective studies did not demonstrate benefit from the addition of 
intrathecal drugs (MTX, cytarabine) in patients treated with HD MTX dosed at 3g/m2 (Class IIIb).29-31 
In contrast, two consecutive single arm trials using the same systemic polychemotherapy regimen 
suggested additional benefit when intraventricular chemotherapy was added (Class IIIa).32,33 However, 
given the low level of evidence, we currently do not advocate IT chemotherapy as prophylaxis.  
 
Rituximab 
 
Based on its poor penetration into the CNS related to its large size, the maximal concentration and 
efficacy of the anti-CD20 antibody rituximab in the CNS might be assumed to occur in the early 
treatment phase, during BBB breakdown within the tumors. The effect of rituximab when used as 
monotherapy in PCNSL was evaluated in a single study in which 12 patients with refractory or 
relapsed PCNSL were treated with a weekly iv dose of 375 mg/m2 rituximab infusion for up to eight 
doses (Class IV).34 MRI responses were observed in 36% of patients. Other studies used iv rituximab 
in combination with a HD MTX-based chemotherapy regimen as initial treatment for newly-diagnosed 
PCNSL or as salvage treatment for recurrent PCNSL (Class IIIa, Class IIIb and IV).16,22,35-41 Three 
studies suggested that the addition of rituximab to HD MTX-based chemotherapy improves the CR 
and OS ratein patients with newly-diagnosed PCNSL based on retrospective comparison with 
historical controls (Class IIIb).39-41 Overall, the addition of rituximab to systemic polychemotherapy is 
well tolerated. Injection of rituximab into the CSF via either lumbar puncture or by intraventricular 
administration was evaluated in phase I for refractory or recurrent CNS lymphoma patients (Class 
IIIa).42 In these studies objective responses and good tolerability were documented confirming small 
case series. In conclusion, the existing level of evidence supporting either systemic or local use of 
rituximab as part of treatment protocol for PCNSL remains low. Yet, the preliminarily available 
information suggests that it may add some benefit. Two ongoing randomized trials (NCT01011920; 
NTR2427) should clarify the role of systemic rituximab in PCNSL.  
 
Radiotherapy 
 
Because of the microscopically diffuse and multifocal nature of PCNSL, radiotherapy (RT) has so far 
involved the whole brain, including the eyes.  Despite a high response rate in the range of 50%, RT 
used as sole treatment modality, provides limited survival benefit in PCNSL patients, with a median 
OS duration of 10–18 months and a 5-year survival rate of 5%. The only phase II trial, conducted by 
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the RTOG, which delivered a total dose of 40 Gy with an additional 20-Gy boost to contrast-
enhancing lesions, reported a disappointing 11.6 month OS (Class IIb).43 In addition, the majority of 
relapses occurred in fields that had received the highest RT dose. Although not formally compared in a 
randomized trial, a wide consensus is shared which considers that HD MTX-chemoradiation is 
superior to RT-alone, allowing for a 2 to 4-fold increase in OS (median: 30-72 months) and long-term 
survivors (5-year survival of 20-50%) for many protocols (Class IIb, IIIa IIIb).15,44-52 In contrast to 
extracerebral NHL, the optimal dose of post-chemotherapy irradiation has never been prospectively 
investigated in PCNSL.53 Doses of 23–50 Gy to the whole brain, with or without a tumor bed boost, 
are currently used, with most of the protocols delivering a total dose of 40–45 Gy without boost, and 
standard fractionation (1.8-2Gy/fraction). The RTOG-9310 trial did not show a clear benefit with 
hyperfractionated WBRT (Class IIb).54 For patients who achieve a CR after HD MTX-based 
chemotherapy, it remains unclear whether consolidation with WBRT provides better disease control or 
survival. There has only been one randomized trial of radiotherapy versus watch-and-wait after 
chemotherapy for PCNSL. This study (G-PCNSL-SG 1) conducted in Germany was a non-inferiority 
phase III trial, in which patients received HD MTX 4g/m2 iv every 14 days for 6 cycles with or 
without ifosfamide. Those patients who achieved a CR had been randomized initially between 
consolidating WBRT, 45 Gy in 30 fractions over 6 weeks or no further immediate treatment. Patients 
without a CR received HD cytarabine or WBRT. A total of 551 patients entered the study, but 318 
patients were treated per-protocol. OS was similar in both arms. In the whole per-protocol population, 
the WBRT arm was associated with a trend (not significant) for better PFS, as compared with the no 
WBRT arm but with no significant difference in OS.20 This trial (Class I), which is, to date, the largest 
one and only phase III trial in PCNSL has raised vigourous debate within the community.55-58 Several 
experts consider that the unmet primary endpoint for non-inferiority and the high rate of protocol 
violations prevent any conclusions being drawn from the trial and advocate keeping consolidation 
WBRT after HD MTX-based chemotherapy as the standard of care, whilst awaiting results from 
further, ongoing randomized trials; while others, acknowledging the methodological limitations of the 
study, consider nevertheless that the results contribute strongly to the accumulating retrospective 
literature suggesting that omission of WBRT from first-line treatment results in shorter PFS but does 
not compromise OS (Class IIIb).29,59,60 In addition, several single arm trials have suggested that 
chemotherapy alone, plus a deferred RT strategy may result in comparable OS with those reported for 
combined chemo-RT but with better neurocognitive preservation (Class IIb, IIIa, IIIb).19,25,26,32,61-63 
Since withdrawing consolidation WBRT for patients with CR to chemotherapy remains controversial, 
especially in patients less than 60 years old who are at lower risk of developing neurotoxicity, reduced 
dose WBRT is another alternative approach. Conflicting results have been reported. A subset analysis 
from a phase II trial that included 25 patients aged <60 years who achieved a CR after initial 
chemotherapy and received either 45 Gy or 30.6 Gy as consolidation treatment showed a significantly 
higher recurrence rate and lower OS rate in the reduced-dose RT group (Class IIIb).64 On the other 
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hand, in a restrospective study of 33 patients with PCNSL who achieved CR after MTX-containing 
chemotherapy and were referred to consolidation WBRT, total doses ≥ 40 Gy were not associated with 
improved disease control in comparison with a WBRT dose of 30-36 Gy (Class IIIb).65 More recently, 
a phase II trial evaluating an immunochemoradiation regimen (R-MPVA) including rituximab and HD 
MTX-based polychemotherapy, the 31 CR patients were offered reduced dose WBRT (23 Gy in 
complete responders) with encouraging results both in term of survival and neurotoxicity (Class IIb).16 
Based on these results, a randomized phase II study (RTOG-1114) comparing the R-MPV regimen 
with or without reduced-dose WBRT is currently ongoing (NCT01399372). In summary, the role of 
consolidation WBRT following HD-MTX based chemotherapy remains debated especially in patients 
in CR. In addition, the optimal dose has not been defined yet. 
 
High-dose chemotherapy, myeloablative conditioning and autologous stem cell transplantation (HDC 
/ASCT) 
 
HDC/ASCT is the standard treatment for chemosensitive relapsing systemic DLBCL. For patients 
with relapsed or refractory PCNSL, there is only one multicenter phase II trial evaluating HDC/ASCT, 
with TBC conditioning regimen (thiotepa, busulfan, cyclophosphamide). The CR rate was 60%, 
median PFS and OS were 41 and 58 months respectively for the 27 patients out of 43 who completed 
the full HDC/ASCT procedure. For the whole population of this trial, the intent-to-treat median PFS 
and OS times were 11 and 18 months respectively. The toxicity-related mortality was 7% (Class IIb).66 
An update of this study to which additional cases have been included, and an independent 
retrospective single center series confirmed the benefit of the TBC regimen followed by ASCT (Class 
IIIb).67,68 Experiences with other HDC regimens in this setting of patients are limited to a few cases, 
which prevent any conclusions being drawn. Because of its toxicity risks, the HDC/ASCT is likely to 
be proposed for younger patients (<60-65 years) with a good performance status, which makes it 
difficult to compare with other salvage treatments, including second-line conventional chemotherapy 
regimens and WBRT. The specific role of HDC/ASCT as consolidation in first-line treatment is 
difficult to evaluate since WBRT was administered after HDC/ASCT in early studies (Class IIb).69,70 
The first study with HDC/ASCT without WBRT used the BEAM regimen (BCNU, etoposide, 
cytarabine, and melphalan) as conditioning and reported a disappointing median event-free survival of 
9.3 months (Class IIIa).71 Subsequently, encouraging studies for which WBRT had been omitted at 
least in patients in CR after HDC/ASCT using HD thiotepa-based conditioning regimens have been 
reported (Class IIIb and IV).72-75 Taken together, although direct comparison between conditioning 
regimens applied is difficult, HD thiotepa-based conditioning regimens seem more efficient than 
BEAM-based regimens. In summary, HDC/ASCT represents an effective treatment option for selected 
refractory and relapsed PCNSL patients, but should be reserved to experienced centers. Superiority of 
the HDC/ASCT approach compared to standard combined chemo-radiotherapy as first line treatment 
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has not been proven and is currently under investigation in two ongoing trials (NCT00863460, 
NCT01011920). 
 
Elderly patients 
 
Definition of ‘elderly’ is not uniform. However, in the studies available which have evaluated 
prognostic factors, older ages (over 50 and over 60) were consistently correlated with worse outcome 
(see the section on prognostic factors in appendix). Furthermore, for chemoradiation-induced 
neurotoxicity age>60 was found to be highly prognostic (see the section on neurotoxicity in appendix). 
Therefore, age of 60 has been used as cut-off to define the elderly population in most of the studies. 
Four prospective studies have been published on treatment of elderly patients with PCNSL (Class 
IIb),36,63,76,77 seven prospective studies on patients of all ages but reporting specifically on older 
patients (Class IIIa),11,12,32,43,52,54,78 and seven retrospective studies reporting on ≥ 15 patients (Class 
IIIb).79-85 As in younger patients, results in patients treated with steroids or CHOP/CHOD in addition 
to radiotherapy do not differ from results after radiotherapy only (Class IIb).11,12,43,77 In the RTOG 
phase II trial, the median survival was only 7.8 months.43 After HD-MTX-based therapy, defined as 
dose of MTX ≥ 1 g/m2 PFS in patients aged 60 or 65 and older is reported between 6 and 16 months 
and OS between 14 and 37 months (Class IIb and Clas III) with OS in the majority of prospective 
studies under 2 years.32,36,52,54,63,73,78-85 Other than within retrospective studies no direct comparisons 
have been made between treatment with HD-MTX-based chemotherapy and radiotherapy in this age 
group.81 However, the impression from the single arm studies is that survival after chemotherapy is at 
least as good and probably better after HD MTX-based chemotherapy than after radiotherapy (Class 
IV). Formal comparisons of different HD MTX-based regimens have not been published but in a 
recently completed randomized phase II study, toxicity was identical, CR rate, median PFS and  
survival appeared better after MPV-A (MTX, procarbazine, vincristine, cytarabine) than after MTX 
and temozolomide though the difference was not significant (Class IIa).86 Five prospective studies 
report on chemotherapy toxicity in patients aged over 60. With the exception of one study, in which an 
intensive multi-drug regimen was used and toxicity was exceedingly high in older patients,52 HD 
MTX-based chemotherapy up to 3.5 g/m2 was well tolerated with 2-7% treatment-related mortality, 
less than 10%  grade 3-4 nephrotoxicity and 7-10% of patients discontinuing treatment due to 
chemotherapy-associated toxicity, though MTX dose was reduced because of decreased renal function 
in 26-44% of patients.36,63,76,87 Retrospective studies substantiate this view. Thus, in general, older 
patients tolerate treatment with HD-MTX well when adequate supportive measures are used and renal 
function is accurately monitored.3 As discussed in the neurotoxicity section (appendix), risk of delayed 
leukoencephalopathy is particularly high in patients older than 60 years managed with 
chemoradiotherapy. For patients treated with HD-MTX-based chemotherapy without radiotherapy no 
studies reporting specifically on older patients are available, but reports including neuropsychological 
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assessment of patients of all ages show little or no cognitive decline compared with post-treatment 
evaluations (Class IIIb).61,88 Given the available data on acute and long-term toxicity of radiotherapy 
and chemotherapy in older patients with performance status KPS ≥ 70, treatment with HD MTX-based 
chemotherapy with deferral or elimination of WBRT is the treatment of choice. In older patients in 
poor condition and in the very old (over 80) who both have a worse prognosis,85 the acute morbidities 
and frequent admissions to hospital associated with HD-MTX chemotherapy need to be individually 
weighed against the more limited survival benefits in this population.  
 
 Salvage treatment 
About one third of patients with PCNSL will present with disease that is refractory to first-line 
treatment and half of responders will relapse despite high response rates seen with initial treatment. 
The prognosis of progressive or relapsed PCNSL remains poor with limited treatment options. Salvage 
treatments for relapsed or refractory PCNSL patients depend on age, performance status, site of 
relapse within the CNS, prior treatments and time duration from last response. If the patient did not 
receive any consolidating treatment after the HD MTX-based induction chemotherapy, WBRT or 
HDC/ASCT should be considered. Two retrospective studies have evaluated WBRT delivered in 
relapsed PCNSL and reported a high rate of objective reponses and a short median survival of 11-16 
months - quite similar to what is expected with WBRT alone as initial treatment (Class IIIb).89,90 
Delayed neurotoxicity occurred in 15%–22% of patients. However, in the setting of recurrence, 
WBRT did not prolong survival compared with non-WBRT-based therapies in the G-PCNSL-SG-1 
trial (Class IIIa).20 HDC/ASCT is an efficient alternative option, as has been previously discussed, and 
which should be preferentially proposed for patients aged < 60-65 years and with a tumour sensitive to 
second-line chemotherapy (Class llb) (see section above).66-68 Otherwise, if the patient is not suitable 
for WBRT or HDC/ASCT , conventional chemotherapy can be proposed as second-line treatment. 
There is however, only a limited number of prospective studies available for guidance and these have 
been single-arm phase ll trials complicating any comparison across trials ( Class llb, lll and lV  for all 
studies in this section ). Several drugs used as single agent or in combination, with or without 
rituximab, have been evaluated and demonstrated modest activity such as temozolomide,38,91 
topotecan,92 pemetrexed,93 bendamustine,94 PCV regimen,95 ifosfamide-etoposide based regimen,37,96, 
or cisplatin-cytarabine based regimen.97 MTX rechallenge given as single agent or in combination may 
also yield a high rate of new objective response and durable remission in patients who previously 
achieved prolonged response with HD MTX-based chemotherapy, suggesting retained 
chemosensitivity to MTX (Class III).98,99 Extra-CNS relapses account for 7% of failures, and some 
studies suggest that extra-CNS relapses are associated with a better prognosis than CNS-involving 
relapses;100 the best salvage treatment for this condition remains to be defined, but excellent results 
have been reported with anthracycline-based chemotherapy consolidated or not with HDC/ASCT.28  
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Conclusions 
Guidelines reflect the state of knowledge at a given timepoint. The EANO website will inform of 
future updates on this guideline (https://www.eano.eu). 
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Table 1:  Consensus statements and recommendations for the general approach to patients with PCNSL 
including establishment of diagnosis, baseline work-up and response to treatment 
 
Diagnosis 
• Cranial MRI with FLAIR and T1 weighted sequences before and after contrast injection is the 
neuroimaging method of choice for the diagnosis and follow-up of PCNSL. Diffusion, dynamic 
susceptibility contrast, proton spectroscopy MRI, and FDG-PET can be useful in the differential 
diagnosis but are not specific (Good Practice Point).   
• The diagnosis of PCNSL requires pathological confirmation before treatment (Good Practice Point).   
• When PCNSL is suspected, the standard surgical procedure for diagnosis is a stereotactic or navigation 
guided needle biopsy (Good Practice Point, see section on surgery for discussion).   
• Because it may prevent the histopathological diagnosis, it is recommended, if clinically possible, to 
avoid steroids before biopsy. In case of remission and/or unspecific inflammation in the tissue biopsied 
in steroid-pretreated patients, rebiopsy is recommended when close and careful follow-up with serial 
MRI indicates further tumor growth (Good Practice Point).   
• PCNSL are diagnosed according to the WHO classification. Immunohistochemistry is required (Good 
Practice Point, see pathology section in the webappendix).  
• Required immunohistochemical markers for the lymphoma cell characterization should include: pan-B 
cell markers  (CD19,CD20,PAX5), BCL6, MUM1/IRF4, CD10 (Good Practice Point). 
• PCR analysis of immunoglobuline gene families may contribute to diagnosis in difficult cases, in 
particular when inflammatory disorders such as multiple sclerosis or corticosteroid-mitigated PCNSL 
are considered. (Good Practice Point). 
• In case of a suspicion of PCNSL, the work-up should include at least an HIV blood test, a lumbar 
puncture (if not contraindicated) and an ophthalmologic evaluation (with a fundoscopy and a slit lamp 
examination) in all patients, including those without ocular symptoms (Good Practice Point).   
• The identification of lymphoma cells in the CSF or the vitreous may obviate the need for a stereotactic 
brain biopsy to confirm the diagnosis only in the setting of high clinical and radiological suspicion of 
PCNSL. As cytologic diagnosis may be difficult, a review by a specialist pathologist is recommended, 
and in any doubt a brain biopsy is required (Good Practice Point). 
• Immunophenotyping by multiparameter flow cytometry of cells collected in the CSF or vitreous and 
immediately analyzed may add to diagnostic sensitivity. 
•  if B-cell monoclonality is shown in a sample with atypical/suspicious cells. PCR based analysis of 
immunoglobulin gene rearrangement in the CSF reportedly may show false positives. Therefore, 
evidence for the clonality of the lymphocytic cell population considered separately remains insufficient 
for the diagnosis for PCNSL except in case of high clinically documented suspicion of PCNSL (Good 
Practice Point).   
Staging  
• Systemic staging should include: physical examination, CT-scan of the chest, abdomen and pelvis, 
testicular sonography and bone marrow biopsy. FDG body PET may represent an improved alternative 
to total body CT-scan and testicular sonography  (Good Practice Point).  
Prognosis 
• Age and performance status have been consistently identified as treatment-independent prognostic 
factors in PCNSL. Evaluating the individual risk of a PCNSL patient before treatment according to one 
of the existing prognostic scores is recommended (Good Practice Point).   
• Age over 60-65 is used to define the elderly population in PCNSL (Good Practice Point).   
Evaluation of response and follow-up 
• The International Primary CNS Lymphoma Collaborative Group (IPCG) criteria (2005) combining 
MRI, eye examination, CSF analysis and steroid dose should be used to evaluate response to treatment 
(Good Practice Point).  
• There is no evidence as yet that brain FDG PET can be used to assess response in PCNSL in the way 
that it is used for other lymphomas (Good Practice Point). 
• Formal prospective neuropsychometric testing is recommended in the follow-up of patients treated in 
clinical trials on PCNSL (Good Practice Point).   
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Table 2: Consensus statements and recommendations for treatment of patients with PCNSL   
 
Surgery 
• Surgical resection may be considered in patients suffering from a large space occupying lesion with 
acute symptoms of brain herniation to reduce rapidly intracranial pressure (Good practice point). 
• In patients with an unifocal and resectable lesion suspected of PCNSL, no consensus was met in the 
panel to recommend either surgical resection or biopsy 
Chemotherapy 
• CHOP-regimens and derivatives are not indicated in PCNSL (Level B). 
• Chemotherapy should include MTX at HD (≥ 3g/m2) both to cross the BBB and yield cytotoxic levels 
in the CSF. It should be delivered in 2-3 hour iv infusions for a minimum of 4-6 injections and at 
intervals that should not exceed 2-3 weeks (Good Practice Point).   
• Combination of HD-MTX with other chemotherapeutic agents improves the response rates with respect 
to HD-MTX alone (Level B).  
• Chemotherapeutic agents to combine with HD MTX should be selected among active drugs known 
to cross BBB, such as HD cytarabine  (Level B). 
• HD-MTX-chemotherapy is feasible in elderly patients with adequate performance status and renal 
function (Level B). 
• BBBD followed by IA MTX is an alternative experimental approach appropriated for a selected group 
of patients that should be undertaken by trained teams only (Level B). 
• The value of IT chemotherapy as prophylaxis is unclear. IT chemotherapy (intralumbar or preferably 
intraventricular through an Ommaya reservoir) can be proposed in case of documented meningeal 
involvement with insufficient response to iv HD MTX (>3g/ m2) based chemotherapy (Good Practice 
Point).   
• Rituximab combined with a chemotherapy regimen is still an experimental regimen that has its main 
place in clinical trials (Level C). 
Radiotherapy 
• WBRT, HD MTX, and a fortiori combined treatment expose patients to an increased risk of 
neurotoxicity (Level A). 
• The role of consolidation WBRT following HD-MTX based chemotherapy remains debated. In 
addition, the optimal dose is not yet defined, but it should be chosen on the base of response to primary 
chemotherapy (Good Practice Point).   
• In patients with progressive or residual disease after primary chemotherapy, a total dose of 40-45 Gy 
with a 1.8-2 Gy dose /fraction appears advisable. With such doses, there is no evidence to add a focal 
boost on the enhancing lesions (Good Practice Point).   
• In patients < 60 years who have achieved a CR to induction chemotherapy, the option of immediate 
WBRT (40 - 45 Gy in 1.8 - 2.0 Gy fractions) or WBRT omission should be discussed with the patient. 
Reduced dose WBRT consolidation (23.4 - 30 Gy in 1.8 - 2.0 Gy fractions) is a therapeutic option that 
should be investigated in a clinical trial (Good Practice Point).   
• In patients > 60 years, the risk of delayed neurotoxicity, after WBRT  (doses >30 Gy in 1.8-2.0 Gy 
fractions ) especially if following HDMTX , is unacceptably high and WBRT at this dose should be 
deferred or avoided (Level B). 
High dose chemotherapy with autologous stem cell transplantation (HDC/ASCT) 
• HDC/ASCT is an efficient treatment in relapsed or refractory PCNSL (Level B).  
• HDC/ASCT should be reserved for patients < 60-65 years (Good Practice Point).   
• High-dose thiotepa-based conditioning chemotherapy should be preferred over the BEAM regimen 
(Level C).  
• HDC/ASCT as consolidation in first-line treatment remains experimental in PCNSL and should be 
restricted by selected trained centers  (Good Practice Point).   
Primary intraocular lymphoma (PIOL) 
• PIOL may be treated by either HD-MTX-based chemotherapy (with or without WBRT) or by local 
therapy (intravitreal chemotherapy or ocular RT) (Good Practice Point).   
• Local treatment (intravitreal chemotherapy or ocular RT) is a valid approach for patients with systemic 
chemotherapy contraindications or for elderly patients with relapsing intraocular disease (Good Practice 
Point).   
• Concurrent intraocular and CNS lymphoma should be treated no differently from PCNSL (Good 
Practice Point).   
• If consolidation WBRT is proposed, it should include both eyes (Good Practice Point).   
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• Refractory and relapsed IOL should be treated according to the patients’ characteristics and prior 
treatments. Treatments include intravitreal injections of MTX, focal radiotherapy, WBRT, systemic 
chemotherapy and HDC/ASCT (Good Practice Point).  
Salvage treatment 
• Patients with relapsed / refractory PCNSL should be enrolled into phase I-II trials (Good Practice 
Point).   
• The choice of the most appropriate salvage treatment should depend upon the patient’s age, 
performance status, comorbidity, site of relapse, prior therapy, and duration of previous response. The 
expected side effects of the chosen drug must also be considered carefully (Good Practice Point).   
• Salvage WBRT may be proposed in radiotherapy-naïve patients; it may be preceded by induction 
chemotherapy (Good Practice Point) 
• HDC/ASCT is a valid therapeutic option in patients aged <60-65 years with chemosensitive relapsing 
PCNSL (Level B). 
• Salvage chemotherapy can be delivered as induction therapy before WBRT or HDC/ASCT, or as 
exclusive treatment in patients not eligible for these therapies.  
• MTX re-challenge should be considered in recurrent PCNSL patients who previously responded to HD 
MTX (Level C). 
• Isolated extra-CNS relapses should be managed with anthracycline-based chemotherapy followed or not 
by HDC/ASCT (Good Practice Point)  
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WEBAPPENDIX 
 
This webappendix summarizes evidences used for EANO`s recommendations for the general approach to 
PCNSL patients with coverage of diagnostic aspects – pathology and genetics, clinical presentation, pathological 
confirmation, neuropathology of corticosteroid-treated PCNSL, cerebrospinal fluid (CSF) analyses, vitreous 
analyses, staging,– as well as prognostic factors, response criteria to treatment, treatment related neurotoxicity 
and treatment of intraocular lymphoma. 
   
Pathology and genetics 
 
PCNSL is a mature B cell lymphoma corresponding to DLBCL of the CNS. Morphologically, haematopoietic 
tumor cells, mostly resembling centroblasts, are scattered throughout the brain tissue and also exhibit a marked 
angiotropism with sheets of tumor cells clustering within and around blood vessel wall. Immunohistochemistry 
is required for the diagnosis. In addition to the expression of pan-B cell markers (CD19, CD20, PAX5), the 
tumor cells of PCNSL are characterized by a BCL6+IRF/MUM1+CD10- immunophenotype with high 
proliferative activity (Ki-67 indexes of 70-90%), together with high expression of the MYC and BCL2 proteins.1-
3
 With rare exception, Epstein-Barr Virus (EBV) is absent from PCNSL of immunocompetent patients. Ongoing 
activity of the germinal center program and blocked terminal B cell differentiation together with pathways 
deregulated by genetic alterations (B cell receptor, toll like receptor, NF-kB pathways) may foster B cell 
activation and brisk proliferation and be of pathogenetic relevance.4-9 Analysis of the molecular landscape of 
PCNSL indicates that aberrant somatic hypermutation which targets several genes (PIM1, TTF, MYC, KLH14, 
OSPL10, SUSD2) may play an important role in the pathogenesis of PCNSL, 9,10 and that alterations in genes of 
role in CNS development may facilitate DLBCL manifestation in the CNS.10 Epigenetic studies revealed 
frequent gene silencing due to CpG island hypermethylation in individual genes including MGMT, CDKN2A, 
and DAPK.11,12 Recurring chromosomal losses affected the 6q, 6p21.32 (HLA locus) and 9p21 (CDKN2A locus) 
regions.5,13  However, to date, no specific molecular genetic signature distinguishes clearly PCNSL from non-
CNS DLBCL, suggesting an important role of the microenvironement in explaining the peculiar behaviour of 
PCNSL. For research, collecting frozen samples and developing a network for PCNSL tumor banks should be 
encouraged. 
 
Diagnosis 
 
Clinical presentation 
Presenting symptoms may include cognitive decline and/or personality changes, focal neurological deficits and 
increased intracranial pressure. Seizures are less frequent (10%). Ocular symptoms, due to an involvement of 
retina, choroid or vitreous, are represented by floaters and/or blurred vision; they can be either isolated (10%) or 
coexist with cerebral symptoms (10-20%). However, up to one-half of patients with PCNSL and ocular 
involvement have no visual symptoms. Insidious onset and delayed diagnosis of intraocular lymphoma are 
common.14 In immunocompetent patients, cranial MRI with contrast enhancement typically shows intense and 
homogeneously enhancing single lesions (70%) or multiple lesions (30%) with  modest surrounding edema, 
usually located in periventricular areas and/or deep gray matter.15,16 Although suggestive, all these MRI findings 
are not specific. Advanced imaging techniques, especially FDG-PET, diffusion tensor imaging, dynamic 
susceptibility contrast MRI (DSC-MRI) and proton MR spectroscopy can increase the diagnostic accuracy and 
help in differentiating PCNSL from other brain tumors or non-tumor lesions.17-26 However, although some 
signatures are highly suggestive of PCNSL, especially when present together (low regional cerebral blood 
volume ratios, high percentage of signal-intensity recovery at the end of the first pass of contrast agent relative to 
baseline, very high lipid resonances), they are not sufficiently specific in practice to replace pathological 
confirmation.   
 
Pathological confirmation  
Diagnosis always needs to be confirmed pathologically, according to the WHO classification in most cases by 
stereotactic needle biopsy.1 In classical cases, combined histology and immunohistochemistry yields the 
diagnosis of PCNSL, i.e. DLBCL of the CNS. In such cases, molecular studies are not required. In equivocal 
cases PCR testing for clonality may aid the diagnosis.27,28  
 
Neuropathology of corticosteroid-treated PCNSL 
As the tumor cells of PCNSL are potentially highly sensitive to corticosteroids, they may undergo rapid 
apoptosis. Transient tumor shrinkage or disappearance of contrast enhancement may occur even after short 
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exposure to steroids in approximately 40% of PCNSL, coupled with significant neurological improvement.29  
Stereotactic or navigation guided needle biopsy in this setting may be non-diagnostic in up to 50% of cases.30 In 
the absence of tumor blasts, resorptive changes with prominent infiltration of macrophages, T cells, reactive 
astrocytes , and prominent microglial activation may prevail. In some cases, a few enlarged B cells may persist, 
being suspicious of blast. In such cases, PCR analysis of immunoglobuline genes may demonstrate 
monoclonality. However, a small number of B cells may pretend monoclonality ("pseudoclonality"). Therefore, 
unless patients are rapidly deteriorating with suggestive radiological features of PCNSL, it is usually 
recommended to defer corticosteroids until histologic confirmation has been obtained. Clinicians referring from 
peripheral hospitals should discuss with the specialist neurosurgical centre before starting corticosteroids. If, 
nevertheless, corticosteroids have been given with a subsequent objective response, tapering corticosteroids 
within one or two weeks and delaying biopsy until tumor regrowth would be a reasonable option. Since regrowth 
occur in most cases within a few weeks after discontinuation corticosteroids, a serial MRI follow-up with one 
month interval may be recommended at least the first three months. If no significant changes in contrast 
enhancement or progression are observed, biopsy seems associated with a relatively good probability of yielding 
a diagnosis despite steroid pre-treatment.31  
 
CSF analysis 
The identification of lymphoma cells in the CSF or in a vitreous biopsy, when possible, may obviate the need for 
a brain biopsy for the diagnostic confirmation, only in the setting of high clinical and radiological suspicion of 
PCNSL. Frequently, CSF is characterized by elevated protein levels in 75% and mild pleiocytosis in 50% of 
patients. However, lymphoma cells are detected in only 10-30% in the CSF.32,33 Cellular immunophenotyping by 
flow cytometry in the CSF and PCR analysis of immunoglobulin heavy and light chain genes may help to 
distinguish malignant cells from reactive lymphocytes by identifying clonal B-cell populations even when 
cytological examination is negative.34,35 However, low cell numbers in the CSF sample are frequently found and 
may make flow cytometric analysis difficult. A relatively high ratio of PCR false negatives has been reported in 
PCNSL.33,36 Different CSF molecular genetic markers and proteins including microRNA (miR-21, miR-19b, and 
miR-92),37 soluble CD19,38 antithrombin III,39 free immunoglobulin light chains,40 and interleukin-10 and 
CXCL13,41 are potentially useful diagnostic biomarkers for PCNSL but require further validation before being 
used in routine practice. As cytologic diagnosis may be difficult, in any doubt or inconsistencies with the patient 
clinical setting, a pathological confirmation by a brain biopsy is recommended.  
 
Vitreous analysis 
Ophthalmologic evaluation includes fundoscopy and slit lamp examination. Fluorescein angiography may be 
useful for lymphomatous involvement of the retina.14 Ophthalmologic involvement has to be confirmed by 
vitreous biopsy when eyes are the unique site of disease. Positive cytology is obtained in 70% of cases in trained 
pathology department. As for CSF, immunophenotyping and detection of IgH or T-cell receptor rearrangements 
by PCR analysis indicating monoclonality are helpful tools for diagnosis.42,43 High levels of interleukin 10 
(IL10) and/or high IL10 / IL6 ratio in ocular fluids are strongly suggestive of B-cell lymphomatous uveitis,44 but 
are not diagnostic.  
 
Staging 
The aims of staging are both to specify the extent of the lymphoma within the CNS and to exclude the presence 
of the disease elsewhere. If not contraindicated and already performed at the diagnostic work-up, all patients 
should have a lumbar puncture for CSF cytology.  Systemic involvement is present in up to 12% of the cases.45,46 
Since identification of a systemic site of the lymphoma has important implications for the treatment strategy, an 
international workshop to standardize baseline evaluation recommended performing at least a CT-scan of the 
chest, abdomen and pelvis, a bone marrow biopsy, a testicular ultrasound in elderly males.47 FDG body PET, 
which is more sensitive than the body CT-scan,48is not yet an established routine diagnostic investigation, but is 
used in some European countries as an integral part of diagnostic work-up.   
 
Prognostic factors 
 
Age and performance status have been consistently recognized as the most important therapy-independent 
prognostic factors.49-53 Based on retrospective cohorts of PCNSL, other variables including serum lactate 
dehydrogenase (LDH) levels, involvement of deep brain structures,53-55 CSF protein levels,50,53 and extent of 
lesions within the CNS (multifocal versus unifocal),52 have been correlated with outcome, and some of them are 
integrated with age and performance status in different prognostic scoring systems. Hence, three clinically 
meaningful prognostic scores are available for PCNSL: the IELSG score,53 the MSKCC score,51 and the 
Nottingham-Barcelona score.52 All of them distinguished 3 different risk groups. Using such scoring systems is 
useful to compare studies in order to avoid as much as possible selection biases. Since then, other prognostic 
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factors have been correlated with unfavorable outcome and need to be validated in independent series: elevated 
FDG uptake on PET,56 chromosome 6q deletion or CDKN2A homozygous deletion in the tumor DNA,5,57 and 
delayed response to initial chemotherapy, as compared to early response.58 Several variables have yielded 
opposite results in retrospective studies, such as apparent diffusion coefficient (ADC) value derived from 
diffusion-weighted imaging,59-61BCL-6 expression analysis,62-66 and MTX exposure reflected by MTX area 
under the curve (AUC).67-70  
 
Response criteria  
 
In 2005 the International Primary CNS Lymphoma Collaborative Group (IPCG) published a consensus opinion 
to standardize response criteria and outcome measures in immunocompetent patients with PCNSL.47 These 
response criteria define CR as complete disappearance of contrast enhancement on MRI, no evidence of ocular 
lymphoma, negative CSF cytology and discontinuation of corticosteroid use for at least 2 weeks prior to the 
evaluation of response. Since corticosteroids may mask presence of residual disease its discontinuation is 
included as an essential requirement. The IPCG also delineated which findings are compatible with unconfirmed 
CR (CRu). It is important to sort out CRu from PR because the latter means failure of primary treatment. 
According to the IPCG outline CRu includes those cases who fulfill the criteria for CR with the following 
limitations: at time of evaluation the patient is still on any dose of corticosteroids, MRI continues to show small 
but persistent enhancing abnormalities related to biopsy/surgical site or to focal hemorrhage, and the follow-up 
ophthalmologic examination shows persistent minor abnormality which is unlikely to represent ocular 
lymphoma. PR is defined as 50% decrease in enhancing tumor or residual disease on eye examinations, or 
persistent or suspicious CSF cytology. Progressive disease (PD) is recognized as 25% increase in the enhancing 
lesion or appearance of any new site of disease in the CNS or as systemic disease, recurrent or new ocular 
disease, or recurrent or positive CSF cytology. Of note, these definitions do not take into account the non-
enhancing lesion best visualized on T2-Flair MRI, whose differential diagnosis may be challenging since it could 
be treatment-related white matter changes (including leukoencephalopathy) but also correspond to infiltrative 
PD.71 There no evidence as yet  that brain FDG PET can be used to assess response in PCNSL in the way that it 
is used  for other lymphomas.    
 
Delayed neurotoxicity 
 
Delayed treatment-related neurotoxicity has been systematically evaluated in few studies (Class II and III). 
However, there is a general perception and agreement, that the combination of HD MTX and WBRT is 
associated with disabling neurotoxicity with an incidence of 25% to 35% and related mortality of 30%.50,72 This 
deleterious treatment complication typically occurs several months to years after successful treatment. 
Neuropsychological examination may confirm impaired psychomotor speed, executive function, attention and 
memory.73 Affected patients show cortical/subcortical atrophy and leukoencephalopathy,73-75 which may leave 
them demented, ataxic and incontinent. Median survival after onset of clinically-evident neurotoxicity is less 
than 1-2 years.50,72,75 Autopsy findings include myelin and axonal loss, gliosis, spongiosis, thinning of white 
matter, small and large vessel disease, and necrosis.75,76 Of note, imaging abnormalities may not always correlate 
with the neurologic impairment severity over time. In a retrospective mono-institutional series analysis of 183 
patients, only the administration of WBRT was identified as an independent risk factor for the development of 
late neurotoxicity: in this series, 2% treated with chemotherapy alone developed clinically-evident neurotoxicity, 
while 33% treated with combination chemo-/radiotherapy were affected. The cumulative incidence of 
neurotoxicity for the whole group was 5% at 2 years and 24% at 5 years, with a substantially higher risk in 
patients ≥ 60 years (Class IIIb).75 They are related to clinically and radiologically overt neurotoxicity. The 
prevalence of treatment-related “subtle” cognitive dysfunction amongst patients treated for PCNSL is probably 
largely underestimated as formal psychometric evaluationshave not been routinely performed in most 
prospective studies. Small case series identified WBRT, and not chemotherapy, as the primary cause of 
neurotoxicity in PCNSL.76,77 These results have been confirmed by 3 long-term evaluations (Class IIIb). 78-80 In 
the most recent analysis of 80 long-term survivors of PCNSL, free of tumor and having completed treatment 
with different regimens at least two years prior to evaluation, those who had received WBRT showed 
significantly lower mean scores in attention and executive function, motor skills, and neuropsychological 
composite score, associated with poorer quality of life measures (Class IIIb).80 Moreover, on brain imaging, 
mean areas of total T2 abnormalities in the WBRT group were more than twice the mean of any other non-
WBRT group. These results caution against the routine administration of WBRT as part of upfront treatment and 
call for the implementation of formal neuropsychometric testing in clinical trials on PCNSL.73  
 
Intraocular lymphoma 
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Intraocular infiltration can be the exclusive site of disease at presentation, the so-called primary intra-ocular 
lymphoma (PIOL), or as a part of PCNSL with concomitant brain or meningeal disease. The optimal treatment 
for intraocular lymphoma is not known. Data on therapy and outcome are scarce and limited to retrospective 
case reports or mostly small series with heterogeneous patient populations and treatments. As many as 90 % of 
patients with PIOL patients consequently develop brain involvement over the course of the disease and 
dissemination to the brain is the main cause of death.14,81 The median survival of isolated PIOL is approximately 
60 months.81,82 Treatment may be focal, including ocular RT (historically, total dose of 35-40 Gy, 2 Gy per 
fraction using opposed lateral beams to include both globes) (Class IV) and intravitreal chemotherapy. 83-86 
Uncontrolled series have reported clinical remission with repeated intravitreal MTX and more recently after 
rituximab injections (Class IV).85,86 Treatment may be also extensive, including systemic chemotherapy and 
WBRT. Intraocular responses have been reported with HD MTX,87 HD cytarabine,88,89 ifosfamide, trofosfamide 
used as single agent,90 with MTX-based polychemotherapy and after HDC/ASCT (Class IV).91 A large 
retrospective multicenter study did not show any difference in PIOL between focal and extensive therapy in 
terms of disease control and survival (Class IIIb).81 Unfortunately, this and other studies failed to provide reliable 
predictors of brain dissemination in PIOL patients; thus, some experts recommend local therapy for disease 
confined to the eyes, but others consider that initial treatment of PIOL should not differ from that of PCNSL i.e. 
high-dose MTX-based polychemotherapy followed, or not, by WBRT in order to eradicate possible concomitant 
microscopic disease in the brain and in the CSF responsible for relapse. In this case, local treatments would 
remain options for refractory or recurrent disease confined to the eyes. The management decision should take 
into account the individual risk of treatment toxicities (including those related to ocular treatment)  and local 
expertise.14,92 When intraocular lymphoma is concurrent with brain lesions, it has not been identified as an 
independent prognostic factor and the prognosis is similar to that of the PCNSL without intraocular disease 
(Class IIIb).93 Accordingly, patients with concomitant intraocular and cerebral disease should be treated no 
differently from PCNSL. The value of additional local ocular treatment (i.e. intravitreal chemotherapy or ocular 
radiotherapy if WBRT has not been delivered) to systemic chemotherapy remains matter of debate, with 
conflicting results in two retrospective studies (Class IIIb). 93,94 
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